

**NOTE: This policy has been revised. The revised policy will be effective April 1, 2025.**

Medical Policy Manual

Medicine, Policy No. 165

## ***Intensity Modulated Radiotherapy (IMRT) of the Thorax, Abdomen, Pelvis, and Extremities***

**Effective:** April 1, 2024

**Next Review:** September 2024

**Last Review:** November 2023

### **IMPORTANT REMINDER**

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

### **DESCRIPTION**

Intensity modulated radiotherapy (IMRT) is a form of radiation therapy that conforms closely to the targeted tumor shape and allows higher doses of radiation to be delivered while minimizing toxicity to surrounding healthy tissues.

### **MEDICAL POLICY CRITERIA**

- I. Intensity modulated radiotherapy (IMRT) of the thorax, abdomen, pelvis, and extremities may be considered **medically necessary** when any of the following criteria are met (NOTE: *This policy addresses specific indications only. Please see Medicine, Policy No. 166 for IMRT for breast cancer and Medicine, Policy No. 167 for requests where only through IMRT can published dose/volume constraints be met for organs at risk*):
  - A. There is documented prior radiation treatment to the planned target volume; or
  - B. To deliver irradiation to the thorax when one or more of the following criteria are met:
    1. Documented curative treatment for any of the following indications:

- a. Esophageal and gastroesophageal junction cancers
  - b. Lung cancer including non-small cell or small cell
  - c. Pleural mesothelioma
  - d. Thymic carcinoma
  - e. Thymoma
- C. For the treatment of soft tissue sarcoma (see Policy Guidelines) when any of the following are met:
- 1. Adjuvant treatment of tumors located in the retroperitoneum, abdomen, pelvis or extremities; or
  - 2. Neoadjuvant treatment of tumors located in the retroperitoneum; or
- D. Primary, adjuvant, or salvage treatment of pancreatic cancer; or
- E. For the treatment of cervical cancer post-hysterectomy or unresectable cervical cancer; or
- F. For the treatment of vulvar or vaginal cancer; or
- G. For the treatment of prostate cancer when any of the following criteria are met:
- 1. Both of the following criteria (a. – b.) are met:
    - a. Primary treatment of local (clinical or pathological T1, T2, N0, M0) or locally advanced (clinical or pathological T3, T4, N0, N1, M0) prostate cancer; and
    - b. Any of the following criteria are met:
      - i. Up to 28 fractions are planned/delivered (ultra- or moderate-hypofractionation); or
      - ii. Over 28 fractions are planned/delivered (conventional fractionation) and documentation is submitted with detailed rationale for medical necessity of more than 28 fractions; or
      - iii. Radiation to the pelvic nodes is included in the treatment plan; or
      - iv. There is documentation of inflammatory bowel disease, mixed connective tissue disorder, or collagen vascular disease; or
  - 2. Low metastatic burden prostate cancer (defined as 5 or fewer bone metastases, no lymph node involvement outside the pelvic lymph nodes, and no visceral metastasis) when all of the following criteria are met:
    - a. Planned target volume includes all oligometastatic foci; and
    - b. The number of fractions meets either of the following criteria:
      - i. Up to 20 fractions are planned/delivered (ultra- or moderate-hypofractionation); or
      - ii. Over 20 fractions are planned/delivered (conventional fractionation) and documentation is submitted with detailed rationale for medical necessity of more than 20 fractions; or

3. Post radical prostatectomy as either adjuvant or salvage treatment when any of the following are met:
  - a. Documentation includes evidence of adverse pathologic findings post-prostatectomy, defined as capsular penetration, seminal vesicle involvement, or positive surgical margins; or
  - b. There is clinical documentation of persistence of detectable PSA post-surgery; or
  - c. Increase in PSA after non-detectability post-surgery, defined as either of the following:
    - i.  $>0.1$ ng/ml, OR
    - ii. An increase on two or more determinations.

H. For the treatment of cancer of the anus/anal canal.

- II. Intensity-modulated radiotherapy (IMRT) is considered **not medically necessary** for the treatment of tumors of the abdomen, pelvis, thorax, and extremities not meeting the criteria above (NOTE: *Please use Medicine, Policy No. 167 for requests where only through IMRT can published dose/volume constraints be met for organs at risk*).

NOTE: A summary of the supporting rationale for the policy criteria is at the end of the policy.

## POLICY GUIDELINES

### ORGANS AT RISK

Organs at risk are defined as normal tissues whose radiation sensitivity may significantly influence treatment planning and/or prescribed radiation dose. These organs at risk may be particularly vulnerable to clinically important complications from radiation toxicity. At-risk organs may include the lungs, heart, and esophagus.

### CANCERS OF THE ABDOMEN AND PELVIS

Cancers of the abdomen and pelvis include, but are not limited to, tumors of the lumbar and sacral spine and pelvic bones, sarcomas, and anal, gastric, pancreatic, hepatobiliary, colon, small bowel, rectal, prostate, and gynecologic tumors.

### HYPOFRACTIONATION FOR PROSTATE CANCER

The following fractionation schedules are recommended by the National Comprehensive Cancer Network (NCCN) for prostate cancer: 20 fractions of 3.0 Gy each, 26 fractions of 2.6 Gy or 28 fractions of 2.5 Gy. Conventional treatment i.e. up to 45 fractions is non-preferred, but appropriate, treatment of men with local or locally advanced presentations regardless of risk group designation as well as those with N1 disease but not for those with limited metastases.

### SOFT TISSUE SARCOMA

The table below indicates which soft tissue sarcomas meet the medical necessity criteria. For those that do not, but only through IMRT can published dose/volume constraints be met for organs at risk, please use Medicine, Policy No. 167.

Location of Primary	Context for Irradiation	
	Neo-adjuvant treatment	Adjuvant treatment
Retroperitoneum	Yes	Yes
Thorax	No*	No*
Abdomen	No*	Yes
Pelvis	No*	Yes
Extremities	No*	Yes

\* Please use Medicine, Policy No. 167 for requests where only through IMRT can published dose/volume constraints be met for organs at risk.

## LIST OF INFORMATION NEEDED FOR REVIEW

### REQUIRED DOCUMENTATION:

It is critical that the list of information below is submitted for review to determine if the policy criteria are met. If any of these items are not submitted, it could impact our review and decision outcome. Quality assurance for 3D and IMRT submitted plans are not required with a preauthorization request.

- Provider consultation and relevant follow-up notes
- Relevant pathology reports
- Relevant imaging reports documenting that the policy criteria are met for medical necessity
- If requesting IMRT for planned conventional fractionation > 28 fractions directed only to the prostate +/- seminal vesicles with no history of collagen vascular disease, additional documentation is required as below:
  - Detailed note explaining clinical rationale for choosing conventional, longer fractionation regimen rather than moderate- or ultra-hypofractionation.

## CROSS REFERENCES

1. [Charged-Particle \(Proton\) Radiotherapy](#), Medicine, Policy No. 49
2. [Intensity Modulated Radiotherapy \(IMRT\) of the Central Nervous System \(CNS\), Head, Neck, and Thyroid](#), Medicine, Policy No. 164
3. [Intensity Modulated Radiotherapy \(IMRT\) for Breast Cancer](#), Medicine, Policy No. 166
4. [Intensity Modulated Radiotherapy \(IMRT\) for Tumors in Close Proximity to Organs at Risk](#), Medicine, Policy No. 167
5. [Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy for Intracranial, Skull Base, and Orbital Sites](#), Surgery, Policy No. 213
6. [Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy for Tumors Outside of Intracranial, Skull Base, or Orbital Sites](#), Surgery, Policy No. 214

## BACKGROUND

### RADIATION TECHNIQUES

#### Conventional External Beam Radiotherapy

Over the past several decades, methods to plan and deliver RT have evolved in ways that permit more precise targeting of tumors with complex geometries. Most early trials used two-dimensional radiation therapy (2D-RT) treatment planning, based on flat images and radiation beams with cross-sections of uniform intensity that were sequentially aimed at the tumor along

two or three intersecting axes. Collectively, these methods are termed conventional external beam radiation therapy (EBRT).

### **Three-Dimensional Conformal Radiation**

Treatment planning evolved by using three dimensional images, usually from computed tomography (CT) scans, to delineate the boundaries of the tumor and discriminate tumor tissue from adjacent normal tissue and nearby organs at risk for radiation damage. Computer algorithms were developed to estimate cumulative radiation dose delivered to each volume of interest by summing the contribution from each shaped beam. Methods also were developed to position the patient and the radiation portal reproducibly for each fraction and immobilize the patient, thus maintaining consistent beam axes across treatment sessions. Collectively, these methods are termed three-dimensional conformal radiation therapy (3D-CRT).

### **Intensity-Modulated Radiotherapy**

IMRT, which uses computer software, CT images, and magnetic resonance imaging (MRI), offers better conformality than 3D-CRT, as it is able to modulate the intensity of the overlapping radiation beams projected on the target and to use multiple-shaped treatment fields. It uses a device (a multileaf collimator [MLC]) which, coupled to a computer algorithm, allows for “inverse” treatment planning. The radiation oncologist delineates the target on each slice of a CT scan and specifies the target’s prescribed radiation dose, acceptable limits of dose heterogeneity within the target volume, adjacent normal tissue volumes to avoid, and acceptable dose limits within the adjoining organs at risk (OAR). Based on these parameters and a digitally reconstructed radiographic image of the tumor and surrounding tissues and organs at risk, computer software optimizes the location, shape, and intensities of the beams ports, to achieve the treatment plan’s goals.

Increased conformality may permit escalated tumor doses without increasing normal tissue toxicity and thus may improve local tumor control, with decreased exposure to surrounding normal tissues, potentially reducing acute and late radiation toxicities. Better dose homogeneity within the target may also improve local tumor control by avoiding underdosing within the tumor and may decrease toxicity by avoiding overdosing. Alternatively, IMRT provides the opportunity to construct heterogenous dose deposition within the target volume thus tailoring differential dose in keeping with physician assessment of differential cancer cell density, etc. This may diminish local failure within the overall target volume.

Because most tumors move as patients breathe, dosimetry with stationary targets may not accurately reflect doses delivered within target volumes and adjacent tissues in patients. Furthermore, treatment planning and delivery are more complex, time-consuming, and labor-intensive for IMRT than for 3D-CRT. Thus, clinical studies must test whether IMRT improves tumor control or reduces acute and late toxicities when compared with 3D-CRT.

## **EVIDENCE SUMMARY**

Multiple-dose planning studies generate three-dimensional conformal radiation (3D-CRT) and intensity-modulated radiotherapy (IMRT) treatment plans from the same scans, and then compare predicted dose distributions within the target area and adjacent organs. Results of such planning studies have shown that IMRT is better than 3D-CRT with respect to conformality to, and dose homogeneity within, the target. Results have also demonstrated that IMRT results in less radiation to nontarget areas. Dosimetry studies using stationary targets

generally confirm these predictions. However, because patients move during treatment, dosimetry with stationary targets only approximate actual radiation doses received. Based on these dosimetry studies, radiation oncologists expect IMRT to improve treatment outcomes compared with those of 3D-CRT.

Comparative studies of radiation-induced adverse effects from IMRT versus alternative radiation delivery would constitute definitive evidence in establishing the benefit of IMRT. Single-arm series of IMRT can give some insights into the potential for benefit, particularly if an adverse effect that is expected to occur at high rates is shown to decrease by a large amount. Studies of treatment benefit are also important to establish that IMRT is at least as good as other types of delivery, but, absent such comparative trials, it is likely that benefit from IMRT is at least as good as with other types of delivery.

In general, when the indication for IMRT is to avoid radiation to sensitive areas, dosimetry studies have been considered sufficient evidence to demonstrate that harm would be avoided by using IMRT. For other IMRT indications, such as using IMRT to provide better tumor control, comparative studies of health outcomes are needed to demonstrate such a benefit.

The focus of the evidence review below is on the indications identified as investigational in the policy criteria.

## **LUNG CANCER**

### **Systematic Reviews**

In 2012, Bejak published a systematic review that examined the evidence for the use of IMRT in the treatment of lung cancer to quantify its potential benefits and make recommendations for RT programs considering adopting this technique within Ontario, Canada.<sup>[1]</sup> This review consisted of two retrospective cohort studies (through March 2010) reporting on cancer outcomes, which was considered insufficient evidence on which to make evidence-based recommendations. These two cohort studies reported on data from the same institution (M.D. Anderson Cancer Center); the study by Liao (2010, reported next)<sup>[2]</sup> acknowledged that patients included in their cohort (n=409) were previously reported on in the earlier cohort by Yom (2007, n=290), but it is not clear exactly how many patients were added in the second report.<sup>[3]</sup> However, due to the known dosimetric properties of IMRT and extrapolating from clinical outcomes from other disease sites, the review authors recommended that IMRT should be considered for lung cancer patients where the tumor is in close proximity to an organ at risk, where the target volume includes a large volume of an organ at risk, or in scenarios where dose escalation would be potentially beneficial while minimizing normal tissue toxicity.<sup>[1]</sup>

### **Randomized Controlled Trials**

Louie (2022) published an RCT that evaluated whether esophageal-sparing IMRT (n=41) achieves a clinically relevant reduction in esophageal adverse events compared with standard RT (n=39) in patients with stage III/IV incurable non-small-cell lung cancer (NSCLC).<sup>[4]</sup> Results demonstrated that the occurrence of the primary outcome, which measured esophageal quality of life two weeks following RT using the esophageal cancer subscale of the Functional Assessment of Cancer Therapy: Esophagus questionnaire, did not significantly differ between treatment groups. However, symptomatic RT-associated esophagitis occurred in 11 patients who received standard RT compared to one patient who received esophageal-sparing IMRT (p=0.002). Overall survival was similar with esophageal-sparing IMRT (median, 8.7 months;

95% CI 5.1 to 10.2 months) and standard RT (median, 8.6 months; 95% CI 5.7 to 15.6;  $p=0.62$ ).

## Nonrandomized Comparative Studies

Peng (2020) performed a retrospective review to compare IMRT, VMAT, and 3D-CRT for concurrent chemoradiation for the treatment of patients with good performance status and unresectable stage III NSCLC.<sup>[5]</sup> Of the 3,872 total patients, 1,178 were treated with 3D-CRT, 1,847 with IMRT, and 847 with VMAT. Median survival in the 3D-CRT, IMRT, and VMAT groups was 21.2 months (95% CI 20.0 to 22.8), 23.9 months (95% CI 22.3 to 25.6), and 24.9 (95% CI 22.5 to 27.4), respectively, which were not significantly different between groups.

Appel (2019) reported outcomes of locally advanced non-small cell lung cancer patients treated with chemoradiation to 60 Gy followed by completion surgery.<sup>[6]</sup> A total of 74 patients, 79.7% of whom were stage 3 received radiation via 3D-CRT (68.9%) or IMRT (31%). Pathological complete response rates in the 3D-CRT and IMRT groups were 33.3 and 34.8%, respectively ( $p=0.9$ ). Two-year local control rates were not significantly different between groups ( $p=0.94$ ) and the combined rate was 81.6% (95% CI 69 to 89.4%). Two-year disease-free survival (DFS; overall 58.3%; 95% CI 45.5 to 69%;  $p=0.33$ ) and three-year OS (overall 70%; 95% CI 57 to 80%;  $p=0.72$ ) were also not significantly different between groups.

Koshy (2017) published a retrospective cohort analysis of patients with stage III NSCLC, comparing those treated with IMRT and with non-IMRT.<sup>[7]</sup> Using the National Cancer Database, 7493 patients treated between 2004 and 2011 were assessed. Main outcomes were OS and the likelihood and effects of radiation treatment interruption, defined as a break in the treatment of four or more days. OS for non-IMRT and IMRT patients, respectively, were 18.2 months and 20 months ( $p<0.001$ ). Median survival with and without a radiation treatment interruption was 16.1 and 19.8 months, respectively ( $p<0.001$ ), and IMRT significantly reduced the likelihood of a radiation treatment interruption (odds ratio [OR], 0.84;  $p=0.04$ ). The study was limited by unavailable information regarding radiation treatment planning and potential mechanisms affecting survival, and by a possible prescription, bias causing patients with better performance status to be given IMRT.

In 2017, Chun reported a secondary analysis of trial that assessed the addition of cetuximab to a standard chemotherapy regimen and radiation dose escalation.<sup>[8]</sup> Use of IMRT or 3D-CRT was a stratification factor in the 2x2 design. Patients were not randomized to IMRT or 3D-CRT. Of 482 patients in the trial, 53% were treated with 3D-CRT, and 47% were treated with IMRT. Compared with the 3D-CRT group, the IMRT group had larger planning treatment volumes (486 mL vs 427 mL,  $p=0.005$ ), larger planning treatment volume/volume of lung ratio (median, 0.15 vs 0.13;  $p=0.13$ ), and more Stage IIIB disease (38.6% vs 30.3%,  $p=0.056$ ). Even though there was an increase in treatment volume, IMRT was associated with less grade three or greater pneumonitis (3.5% vs 7.9%,  $p=0.039$ ) and a reduced risk (OR 0.41; 95% confidence interval [CI], 0.171 to 0.986;  $p=0.046$ ), with no significant differences between the groups in two-year overall survival, progression-free survival, local failure, or distant metastasis-free survival.

Ling (2016) compared IMRT and 3D-CRT in patients with stage III NSCLC treated with definitive RT.<sup>[9]</sup> In this study of 145 consecutive patients treated between 1994 and 2014, the choice of treatment was at the treating physician's discretion, but all IMRT treatments were performed in the last five years. Ling found no significant differences between the groups for any measure of acute toxicity (grade  $\geq 2$  esophagitis, grade  $\geq 2$  pneumonitis, percutaneous

endoscopic gastrostomy, narcotics, hospitalization, or weight loss). There were no significant differences in oncologic and survival outcomes.

Harris (2014) compared the effectiveness of IMRT, 3D-CRT, or 2D-RT in treating stage III non-small-cell lung cancer (NSCLC) using a cohort of patients from the Surveillance, Epidemiology, and End Results–Medicare database treated between 2002 and 2009.<sup>[10]</sup> OS was better with IMRT and 3D-CRT than with 2D-CRT. In univariate analysis, improvements in OS (HR=0.90, p=0.02) and cancer-specific survival (HR=0.89, p=0.02) were associated with IMRT. However, IMRT was similar to 3D-CRT after controlling for confounders in OS and cancer-specific survival (HR=0.94, p=0.23; HR=0.94, p=0.28, respectively). On multivariate analysis, toxicity risks with IMRT and 3D-CRT were also similar. Results were similar for the propensity score–matched models and the adjusted models.

In 2013, Shirvani reported on an M.D. Anderson Cancer Center study on the use of definitive IMRT in limited-stage small cell lung cancer treated with definitive RT.<sup>[11]</sup> In this study of 223 patients treated from 2000 to 2009, 104 received IMRT and 119 received 3D-CRT. Median follow-up times were 22 months (range, 4 to 83 months) for IMRT and 27 months (range, 2 to 147 months) for 3D-CRT. In either multivariable or propensity score–matched analyses, OS and disease-free survival did not differ between IMRT and 3D-CRT. However, rates of esophagitis-related percutaneous feeding tube placements were lower with IMRT (5%) than 3D-CRT (17%; p=0.005).

The 2010 nonrandomized comparative study by Liao compared patients who received one of three forms of RT, along with chemotherapy, for inoperable NSCLC at one institution.<sup>[2]</sup> This study retrospectively compared 318 patients who received CT plus 3D-CRT and chemotherapy from 1999 to 2004 (mean follow-up, 2.1 years) to 91 patients who received four-dimensional CT plus IMRT and chemotherapy from 2004 to 2006 (mean follow-up, 1.3 years). Both groups received a median dose of 63 Gy. Disease end points were locoregional progression, distant metastasis, and OS. Disease covariates were gross tumor volume (GTV), nodal status, and histology. The toxicity end point was grade three, four, or five radiation pneumonitis; toxicity covariates were GTV, smoking status, and dosimetric factors. Using Cox proportional hazards models, the hazard ratios (HRs) for IMRT were less than one for all disease end points; the difference was significant only for OS. The median (SD) survival was 1.40 (1.36) years for the IMRT group and 0.85 (0.53) years for the 3D-CRT group. The toxicity rate was significantly lower in the IMRT group than in the 3D-CRT group. The V20 (volume of the lung receiving 20 Gy) was higher in the 3D-CRT group and was a factor in determining toxicity. Freedom from distant metastasis was nearly identical in both groups. The authors concluded that treatment with 4D-CT plus IMRT was at least as good as that with 3D-CRT in terms of the rates of freedom from locoregional progression and metastasis. This retrospective study found a significant reduction in toxicity and improvement in survival. The nonrandomized, retrospective aspects of this study from one center limit the ability to draw definitive treatment conclusions about IMRT.

## Summary

For the treatment of lung cancer, no RCTs were identified that compared IMRT with 3D-CRT. Dosimetry studies have reported that IMRT can reduce radiation exposure to critical surrounding structures, especially in large lung cancers. Based on nonrandomized comparative studies, IMRT appears to produce survival outcomes comparable with those of



3D-CRT with a reduction in adverse events. Interpretation of these studies is limited by the potential for bias in treatment assignment and/or change in treatments over time.

## ESOPHAGUS CANCER

The esophagus is considered to be an organ at risk as it may be particularly vulnerable to clinically important complications from radiation toxicity. In addition, the thoracic esophagus is in close proximity to vital structures including the heart and lungs. Therefore, conformal radiation therapy is an appropriate delivery method for radiation therapy for esophageal cancer. Studies comparing IMRT to less conformal techniques are discussed below.

Lan (2020) performed a propensity-score based comparison of IMRT and 3D-CRT in patients with esophageal cancer who underwent definitive chemoradiation therapy.<sup>[12]</sup> A total of 297 IMRT-treated and 91 3D-CRT-treated patients were analyzed. IMRT was significantly associated with superior OS ( $p=0.001$ ), PFS ( $p=0.008$ ), and distant metastasis-free survival ( $p=0.011$ ). Locoregional failure-free survival was not significantly different between treatment groups ( $p=0.721$ ). Risk of radiation pneumonitis was significantly lower in the IMRT group (5.4% vs. 23.1%;  $p<0.001$ ). A multivariate analysis indicated that smoking history (OR 4.225,  $p=0.002$ ), primary tumor length (OR 2.764,  $p=0.049$ ), radiation modality (OR 10.760,  $p<0.001$ ), planning target volume (OR 1.004,  $p<0.001$ ), and lung V20 (OR 1.286,  $p=0.002$ ) were found to be significant predictors of radiation pneumonitis.

In 2017, Ito retrospectively analyzed 80 patients with esophageal cancer treated with chemoradiotherapy and compared outcomes of those receiving IMRT and 3D-CRT.<sup>[13]</sup> IMRT and 3D-CRT were reported to have three-year OS of 81.6% and 57.2%, respectively. In a univariate analysis, IMRT patients had significantly better three-year OS but groups were not different in locoregional control or PFS. A multivariate analysis indicated IMRT as the only independent favorable factor for OS ( $p=0.045$ ). Of the 62 cases with nodal involvement, 9.6% developed upper cervical node recurrence outside the prophylactic region. Salvage was successful in 10 of the IMRT patients and 20% of the 3D-CRT patients. Survival without recurrence was reported in 60% of the IMRT group.

Haefner (2017) retrospectively analyzed 49 3D-CRT and 44 IMRT patients who received definitive radiation for locally advanced esophageal cancer.<sup>[14]</sup> Patients were followed up for a mean of 34.7 months. The three-year local relapse rate was 28.6% and 22.7% for the 3D-CRT and IMRT group, respectively. Median progression-free and overall survival in the 3D-CRT group were 13.8 and 18.4 months, respectively. Survival was not significantly different in the IMRT group, where progression-free and overall survival were 16.6 and 42 months, respectively.

In 2017, Xu performed a systematic review and meta-analysis of studies using IMRT and 3D-CRT to treat esophageal cancer.<sup>[15]</sup> Dose-volume histograms, overall survival (OS), and toxicity were analyzed in 80, 871, and 205 patients, respectively. Patients had lower average irradiated volumes in heart and lung from IMRT compared to 3D-CRT. Higher OS was observed in IMRT-treated patients, although there was no significant difference in the incidence of radiation pneumonitis or radiation esophagitis.

Yang (2017) evaluated the effectiveness and toxicities of 3D-CRT, IMRT, and volumetric modulated arc therapy (VMAT) in treating cervical esophageal cancer in a prospective comparative study.<sup>[16]</sup> The two-year OS was 53.6, 55.6, and 60.6% ( $p=0.965$ ) and the two-year failure free survival was 49.5, 56.7, and 60.1% ( $p=0.998$ ) for the 3D-CRT, IMRT, and VMAT

groups, respectively. There was an advantage of treatment modality with respect to OS ( $p < 0.001$ ), as determined by a univariate analysis of the complete response to treatment. There were significantly fewer occurrences of Grade one radiation pneumonitis in patients treated with IMRT and VMAT as compared to 3D-CRT.

In addition, case series and retrospective studies have reported superior dose conformity and homogeneity, as well as superior survival outcomes and reduced radiation dose to the heart and lungs with IMRT compared with 3D-CRT for esophageal cancer.<sup>[17-21]</sup>

## **MALIGNANT PLEURAL MESOTHELIOMA**

### **Systematic Reviews**

Chi (2011) report on a systematic review of IMRT as part of trimodal therapy (surgery, chemotherapy and radiation) for treatment of malignant pleural mesothelioma (MPM).<sup>[22]</sup> However, search criteria were not expressed a priori and the quality of studies was not critically appraised; therefore, interpretation of results from this review is limited.

Another systematic review of radiotherapy in general and IMRT specifically was published in 2011 by Price.<sup>[23]</sup> No randomized controlled trials were identified involving use of these therapies after surgical resection. Available evidence for IMRT consisted of case series, and reports of pulmonary toxicity with IMRT lead the author to conclude that additional studies are needed to establish the factors which differentiate those pre-disposed to adverse effects from radiation therapy from those not at risk. Based upon the available state of evidence, the review stated, "Much work has gone into exploring methods of radical treatment in the few thought suitable for this treatment, again without any evidence that such treatment is of any value, and very little into the palliation of symptoms for what remains an incurable disease in all who present with it." Therefore, the review concluded that, "There is currently no evidence to support the routine role of radiotherapy in patients with mesothelioma."

In 2006, Chapman conducted a systematic review on the use of any radiation therapy in the treatment of MPM.<sup>[24]</sup> The authors were unable to find any literature that met the prespecified inclusion criteria (randomized controlled trial comparing patients treated with radiation therapy with a control group).

### **Nonrandomized Studies**

Since the above systematic reviews, two nonrandomized comparative studies were identified that reported on comparisons of primary health outcomes (e.g., overall-, disease-, or progression-free survival).

Foroudi (2017) reported survival, progression, and toxicity from a retrospective study of high-dose hemithorax radiotherapy for MPM patients.<sup>[25]</sup> A total of 71 patients received doses of 45-60 Gy delivered by 3D-CRT in 17 patients and IMRT in 54 patients. Median overall survival of patients treated with 3D-CRT was 8.1 months (95%CI 5.2 to 19.4) and of patients treated with IMRT was 10.0 months (95% CI 7.2 to 14.0). Median progression free survival of patients treated with 3D-CRT and IMRT was 4.4 months (95% CI 3.3 to 5.5) and 5.4 months, respectively. Grade 3-5 toxicities were reported in 53% of 3D-CRT and 78% of IMRT patients. The authors concluded that high-dose radiotherapy to the hemothorax in MPM patients does not improve survival but does cause significant toxicity.

Shaikh (2017) retrospectively analyzed outcomes in MPM patients who received adjuvant chemotherapy and hemithoracic intensity-modulated pleural RT or adjuvant conventional RT following lung-sparing pleurectomy/decortication.<sup>[26]</sup> The IMRT group had significantly higher OS (median 20.2 (95% CI 13.5 to 28.2) versus 12.3 months (95% CI 10 to 15.3),  $p=0.0001$ ). This group also had significantly higher rates of epithelioid histological type, which was significantly associated with longer OS in multivariate analysis, advanced pathological stage, and chemotherapy treatment. Grade 2 or higher esophagitis was reported in 23% and 47% of IMRT and conventional RT patients, respectively. The one-year incidences of local failure were 42% and 47% for IMRT and conventional RT, respectively, which were not significantly different.

## Section Summary

In summary, there is limited evidence regarding the role of IMRT in the treatment of MPM. Well-designed comparative studies are needed to isolate the treatment effect of radiation therapy from other components of care, and to firmly establish treatment timing and dosing guidelines.

## THYMUS TUMORS

Published literature on IMRT for the treatment of thymomas and thymic carcinoma was summarized in a 2013 systematic review.<sup>[27]</sup> Giannopoulou reported that the treatment of choice is tumor resection in patients who are surgical candidates. Postoperative radiotherapy is recommended based upon a five-year survival of 50-60%. For unresectable disease concurrent chemotherapy and radiation therapy is recommended. The optimal tumor target definition was found with 3D RT, 4D RT, IMRT, image-guided RT, and computed tomography fusion with PET scan.

No new randomized controlled trials or comparative studies have been published since the systematic review.

## SOFT TISSUE SARCOMA

Wang (2019) reported results of a prospective single institution study comparing methods of adjuvant EBRT for extremity or trunk soft tissue sarcoma. IMRT or 2D RT was delivered four to six weeks post-surgery.<sup>[28]</sup> A total of 274 consecutive patients with nonmetastatic soft tissue sarcoma of the extremities and trunk were treated post-operatively. Of these, 187 received IMRT and 87 received 2D-RT. The median follow-up was 48.1 months. Higher five-year local recurrence-free survival (91.1% vs 80.8%;  $p=0.029$ ), distant metastasis-free survival, and overall survival were reported for the IMRT group compared to the group receiving conventional EBRT. Additionally, a multivariate analysis indicated that IMRT was an independent predictor of better local recurrence-free survival, distant metastasis-free survival, disease-free survival, and OS. Significantly fewer incidences of Grade 2 or higher joint stiffness were reported in the IMRT group.

Folkert (2014) performed a retrospective database analysis comparing conventional EBRT and IMRT as adjuvant treatment for soft tissue sarcoma of the extremities.<sup>[29]</sup> Conventional EBRT was the only form of RT reported here prior to 2002 and IMRT was the predominant method after 2006. Patients treated with IMRT had significantly shorter follow-up (90 months for EBRT vs. 42 months for IMRT;  $p<0.01$ ), more high-grade lesions ( $p=0.05$ ) or positive margins ( $p=0.04$ ), and more preoperative radiation ( $p<0.001$ ) and nerve manipulation ( $p=0.04$ ).

However, the groups were comparable with respect to tumor location, histology, tumor size, depth, and use of chemotherapy. According to a multivariate analysis, IMRT was a significant independent predictor of reduced local recurrence (HR=0.458; 95% CI, 0.235 to 0.891; p=0.02). Grade 2 or greater radiation dermatitis occurred in 48.7% of the conventional EBRT patients and 31.5% of the IMRT patients.

Additionally, a number of noncomparative studies have reported outcomes in soft-tissue sarcoma patients treated with IMRT.<sup>[30-36]</sup> These studies have generally reported positive outcomes associated with IMRT, including good local control and low toxicities.

## **STOMACH CANCER**

### **Systematic Reviews**

Ren (2019) completed a systematic review and meta-analysis that evaluated the efficacy and safety of IMRT versus 3D-CRT. Nine controlled clinical trials enrolling 516 patients with gastric cancer were included.<sup>[37]</sup> Results revealed a slightly improved three-year OS rate (risk ratio [RR], 1.16; 95% CI 0.98 to 1.36) and a significantly better two-year OS rate with IMRT (RR, 2.49; 95% CI 1.18 to 5.25; p=0.02) as compared to 3D-CRT. Additionally, the three-year rate of locoregional recurrence was improved with IMRT versus 3D-CRT (RR, 0.62; 95% CI 0.39 to 0.98; p<0.05). Rates of three-year disease-free survival were similar between the radiation modalities (RR, 1.16; 95% CI 0.95 to 1.43; p>0.05). No significant differences in liver, GI, and kidney toxicity were observed between groups. Limitations of this analysis included the small number of enrolled subjects (the majority of studies had <100 subjects), the retrospective nature of included studies, which increased the risk of selective reporting bias, and the heterogeneity of IMRT or 3D-CRT techniques in studies. Additionally, the detail and radiation fields of RT varied considerably among the studies, potentially impacting efficacy and toxicity.

### **Nonrandomized Studies**

In a small (n=7) case series, Milano (2006) reported clinical outcomes of patients with stage III gastric cancer receiving postoperative chemoradiotherapy with 5-fluorouracil (5-FU) and leucovorin and IMRT delivered to a dose of 50.4 Gy in 1.8 Gy fractions.<sup>[38]</sup> Chemoradiotherapy with IMRT was well tolerated, with no acute gastrointestinal (GI) tract toxicities (nausea, diarrhea, esophagitis) greater than grade 2.

Boda-Heggemann (2006) evaluated the efficacy and safety of two different adjuvant chemoradiotherapy regimens using 3D-CRT (n=27) or IMRT (n=33) in two consecutive cohorts of patients who underwent primarily D2 resection for gastric cancer.<sup>[39]</sup> The cohorts in this study were generally well-matched, with American Joint Committee on Cancer (AJCC) advanced stage (II-IV) disease. The majority (n=26, 96%) of those who received 3D-CRT were treated with 5-fluorouracil plus folinic acid (5FU/FA); the other patient received oxaliplatin plus capecitabine (XELOX). In the 3D-CRT cohort, 13 (50%) patients completed the 5FU/FA regimen, 13 halted early because of acute toxicity or progression, and received a median 60% of planned cycles. Patients in the IMRT cohort received XELOX (n=23, 70%) or 5FU/FA (n=10, 30%). Five of 10 (50%) patients completed all planned 5FU/FA cycles; the other five received only a median 60% of cycles because of acute toxicity. Thirteen (56%) treated with XELOX completed all planned cycles; the other 10 received a median of 70% planned cycles because of toxicity. Radiation was delivered to a total prescribed dose of 45 Gy/1.8 Gy/fraction in 21 (81%) of the 3D-CRT cohort patients; five received < 45 Gy because of intolerance to treatment. Thirty (91%) patients in the IMRT cohort received the planned 45 Gy dosage; two

(6%) were unable to tolerate the full course, and one case planned for 50.4 Gy was halted at 47 Gy. Overall, the IMRT chemotherapy regimen decreased renal toxicity with a trend toward improving survival (see Table 1). However, interpretation of this study regarding the safety and efficacy of IMRT is limited by differences in the chemotherapy regimens.

**Table 1. Outcomes for Intensity-Modulated Radiotherapy With Capecitabine Plus Oxaliplatin vs Three-Dimensional Conformal Radiation With 5-FU/FA for Stomach Cancer**

Comparison	3-Dimensional Conformal Radiation	Intensity-Modulated Radiotherapy	p
Sample	27	38	
Renal toxicity, n(%)	2 (8%)	0%	0.021
Median disease-free survival, mo	14	35	0.069
Median overall survival, mo	18	43	0.060
Actuarial 2-yr overall survival, %	37%	67%	
Actuarial 5-yr overall survival, %	22%	44%	

5-FU/FA: 5-fluorouracil plus folinic acid.

The median OS was 18 months in the 3D-CRT cohort, and more than 70 months in the IMRT cohort ( $p=0.0492$ ). The actuarial two-year OS rates were 67% in the IMRT cohort and 37% in the 3D-CRT group ( $p$  not reported). Acute renal toxicity based on creatinine levels was generally lower in the IMRT cohort compared to the 3D-CRT group, with a significant difference observed at six weeks ( $p=0.0210$ ). In the 3D-CRT group, LENT-SOMA grade 2 renal toxicity was observed in two patients (8%) whereas no grade 2 toxicity was reported in the IMRT group.

In an update of this study, which included 27 3D-CRT patients and 38 IMRT patients, authors reported the actuarial five-year OS rates were 47% in the IMRT group and 26% in the 3D-CRT group.<sup>[40]</sup> The median DFS times were 35 months in the IMRT group and 14 months in the 3D-CRT group, ( $p=0.0693$ ). Actuarial five-year DFS survival rates were 44% in the IMRT group and 22% in the 3D-CRT group. Interpretation of this study is limited by differences in the chemotherapy regimens for the 3D-CRT and IMRT groups.

At the two-year follow-up point, the authors of this study assert that adjuvant IMRT with XELOX is more efficacious and associated with less renal toxicity than 3D-CRT with 5FU/FA in patients with advanced gastric cancer. However, a statistically significant difference in chemotherapy regimens was not observed within the IMRT cohort at the five-year follow-up point.<sup>[40]</sup> Among patients receiving 5-FU/FA, DFS tended to be better in the IMRT group, but this was also not a statistically significant observation. In addition, the nonconcurrent cohorts study design precludes direct comparison of outcomes data and conclusions about the relative efficacy of these radiotherapy modalities in this setting.

A small non-randomized study compared the clinical outcomes and toxicity in patients with gastric or gastroesophageal junction cancer who postoperatively received concurrent chemotherapy and either IMRT ( $n=31$ ) or 3D-CRT ( $n=26$ ).<sup>[41]</sup> Dose volume histogram parameters for kidney and liver were compared between treatment groups. The two-year OS rates were not significantly different between the groups (51% for 3D CRT and 65% for IMRT). The groups experienced similar rates of locoregional failures (15% 3D CRT vs. 13% IMRT) and Grade  $\geq 2$  acute gastrointestinal toxicity (61.5 3D CRT vs. 61.2% IMRT); however, the 3D

CRT group needed more treatment breaks (three vs. zero). IMRT was found to provide sparing to the liver and possibly renal function.

Additional publications of IMRT for gastric cancer consist of case series.<sup>[42-49]</sup>

## HEPATOBIILIARY CANCER

### Nonrandomized Studies

Matoba (2020) retrospectively analyzed 15 HCC patients treated with stereotactic body radiotherapy (SBRT) delivered with IMRT to regional lymph node metastases.<sup>[50]</sup> For solitary lesions, a total dose of 45 Gy was delivered in six fractions, and for multiple lesions, 49.5 Gy was delivered over nine fractions. The median follow-up was 18.1 months. The one- and two-year outcomes were 100% and 90±9.5%, respectively, for freedom from local progression, and 73.33±11.4% and 28.6±12.7%, respectively for OS. The one-year PFS rate was 46.7±12.9%. No grade 3 or higher toxicities were reported.

In a retrospective series with a historical control cohort, Fuller (2009) reported that clinical results achieved with image-guided IMRT (n=24) were compared to results with CRT (n=24) in patients with primary adenocarcinoma of the biliary tract.<sup>[51]</sup> The majority of patients underwent postsurgical chemoradiotherapy with concurrent fluoropyrimidine-based regimens. IMRT treatment plans prescribed 46 to 56 Gy to the planning target volume (PTV) that includes the tumor and involved lymph nodes, in daily fractions of 1.8 to 2 Gy. CRT involved 3D planning that delivered 46 to 50 Gy in 1.8 to 2 Gy daily fractions. Both groups received boost doses of 4 to 18 Gy as needed. The median estimated OS for all patients who completed treatment was 13.9 months (range: 9.0 to 17.6); the IMRT cohort had median OS of 17.6 months (range: 10.3 to 32.3), while the CRT cohort had a median OS of 9.0 months (range: 6.6 to 17.3). Acute gastrointestinal toxicities were mild to moderate, with no significant differences between patient cohorts. These results suggest that moderate dose escalation via conformal radiotherapy is technically and clinically feasible for treatment of biliary tract adenocarcinoma. However, while this series represents the largest group of patients with this disease treated with IMRT, generalization of its results is limited by the small numbers of patients, use of retrospective chart-review data, nonrepresentative case spectrum (mostly advanced/metastatic disease), and comparison to a nonconcurrent control radiotherapy cohort.

Two single arm studies reported outcome with IMRT in patients with hepatobiliary cancers. The first study, from Jang (2009), included 42 patients with advanced (33% AJCC stage IIIC, 67% stage IV) hepatocellular carcinoma (HCC) with multiple extrahepatic metastases.<sup>[52]</sup> Among the 42 cases, 33 (79%) had intrahepatic HCC with extrahepatic metastases, 9 (21%) had only extrahepatic lesions. The extrahepatic locations of HCC metastatic lesions included lung (n=19), lymph node and adrenal (n = 20), other soft tissues (n = 6), and bone (n = 5). Helical tomotherapy was performed simultaneously for all lesions in each patient, with a total radiation dose of 50 and 40 Gy to 95% of the GTV and PTV in 10 fractions divided over two weeks. All received capecitabine during the course of IMRT as a radiosensitizer. After completion of tomotherapy, additional transarterial or systemic chemotherapy was administered to patients eligible for it according to tumor location. Among 31 patients who underwent hepatic IMRT, a mean of three courses (range one to six) transarterial chemolipiodolization was performed in 23. Among nine patients with extrahepatic lesions only, three received an additional three-seven cycles of systemic chemotherapy consisting of epirubicin, cisplatin, and 5FU. Median follow-up was 9.4 months (range, 1.9 to 25.3 months). Tumor response was reported separately for each organ treated with IMRT. The overall

objective tumor response rate was 45% for intrahepatic HCC, 68% for pulmonary lesions, 60% for lymph node and adrenal cases, and 67% for soft-tissue metastases. Three cases of local tumor progression occurred within the target radiation area, including two intrahepatic HCC and one abdominal lymph node metastasis. Median OS was 12.3 months, with 15% OS at 24 months. The most common acute adverse events were mild anorexia and constitutional symptoms that occurred one-two weeks after start of IMRT, regressed spontaneously or subsided with symptomatic care, and did not interfere with the scheduled delivery of IMRT. However, it is not possible to discern the impact of IMRT on adverse events because almost all occurred in patients who received chemotherapy following IMRT. Most patients were reported to have tolerated therapy well, with no treatment-related mortality.

A second retrospective single-arm study (McIntosh 2009) involved 20 patients with primary, unresectable HCC who were treated with IMRT and concurrent capecitabine.<sup>[53]</sup> Patients had AJCC grade T1 (n=7) and T3 (n=13) HCC. IMRT was prescribed to a minimum tumor dose of 50 Gy in 20 fractions over four weeks, with the optimization goal of delivering the prescription dose to 95% of the PTV. Capecitabine was administered as radiosensitizer on the days of IMRT delivery. Eleven (55%) patients underwent at least one transarterial chemoembolization (range one-three procedures) before radiotherapy planning. Eighteen of 20 (90%) patients completed the full course of IMRT, two died before follow-up imaging was obtained. The mean survival of 18 patients who completed IMRT was 9.6 months after its conclusion. Disease progression occurred in-field in three patients, two failed elsewhere in the liver. Four patients (25%) required hospitalization during therapy, due to encephalopathy (n=1), gastric ulcer (n=1), acute hepatitis (n=1) and sepsis (n=1). Four required a break from chemotherapy because of peripheral neuropathy (n=2), acute hepatitis (n=1), and sepsis (n=1). Grade 1 acute abdominal pain was observed in 15%, 30% reported grade 1 nausea, 5% experienced grade 2 nausea. No acute or late toxicity greater than grade two was reported.

In a small case series (n=40), Ren (2011) reported the outcomes of irradiation dose escalation in patients with locally advanced hepatocellular carcinoma treated with a combination of 3D CRT/IMRT and transcatheter arterial chemoembolization.<sup>[54]</sup> The authors report that irradiation dose was safely escalated by using 3D/IMRT with an active breathing coordinator to a maximum tolerated dose of 62 Gy for patients with tumor diameters of <10 cm and 52 Gy for ≥10 cm. However, the findings are not reported for each radiation type separately.

Additional publications of IMRT for hepatobiliary cancer consist of similar case series.<sup>[55]</sup> However, similar to the limitations found in IMRT for gastric cancers, evidence regarding IMRT for hepatobiliary cancers is limited by a lack of concurrent comparison groups, small sample sizes and nonrepresentative patient samples. Therefore, it is not possible to draw conclusions about the relative clinical efficacy or toxicities of IMRT in patients with hepatobiliary cancer versus any other radiotherapy method.

## **PANCREATIC CANCER**

### **Nonrandomized Studies**

In 2016, Lee reported a prospective comparative study of gastrointestinal (GI) toxicity in patients treated with concurrent chemoradiotherapy with IMRT (n=44) or 3D-CRT (n=40) for treatment of borderline resectable pancreatic cancer.<sup>[56]</sup> Selection of treatment was by patient choice after explanation by a radiation oncologist. Symptoms of dyspepsia, nausea/vomiting, and diarrhea did not differ between the groups. Upper endoscopy revealed more patients with gastroduodenal ulcers in the 3D-CRT group (42.3%) than in patients treated with IMRT (9.1%;

p=0.003; see Table 2). OS was longer in the IMRT group (22.6 months) compared to the 3D-CRT group (15.8 months; p=0.006), but interpretation of this result is limited by risk of bias in this nonrandomized study.

**Table 2. Outcomes for Intensity-Modulated Radiotherapy vs Three-Dimensional Conformal Radiation for Pancreatic Cancer**

Comparison	3-Dimensional Conformal Radiation	Intensity-Modulated Radiotherapy	p
Sample	40	44	
Gastroduodenal ulcers	42.3%	9.1%	0.003
Overall survival, mo	22.6	15.8	0.006

Prasad (2016) conducted a retrospective study of IMRT (n=134) versus 3D-CRT (n=71) in patients with locally advanced pancreatic cancer.<sup>[57]</sup> The institutional transition from 3D-CRT to IMRT for pancreatic cancer occurred in 2007. Propensity score analysis was performed to account for potential confounding variables, including age, gender, radiation dose, RT field size, and concurrent radiotherapy. Grade II GI toxicity occurred in 34% of patients treated with 3D-CRT compared to 16% of IMRT patients (propensity score odds ratio, 1.26; 95% confidence interval [CI], 1.08 to 1.45; p=0.001). Hematologic toxicity and median survival (15.3 months) was similar in the two groups.

In 2007 Fuss reported the largest series, which involved a retrospective analysis of 41 patients who received image-guided IMRT alone, postsurgically (41%), or with a number of concurrent primarily fluoropyrimidine-based chemotherapy regimens (88%).<sup>[58]</sup> The prescribed radiation dose to the PTV ranged from 41.4 to 60.4 Gy in daily fractions of 1.8 to 2 Gy. For all patients diagnosed with adenocarcinoma (85%), one- and two-year actuarial OS were 38% and 25%, respectively; median OS in resected patients was 10.8 months (range: 6.2–55.1), as compared to 10.0 months (range: 3.4 to 28.0) in inoperable cases. Four patients (9.7%) were unable to complete radiotherapy as prescribed. Any upper GI acute toxicity (none grade 4) was reported in 29 (70%) patients, most commonly nausea, vomiting, and abdominal pain; any lower GI acute toxicity (less than 5% grade 4) was reported in 17 (42%) cases, primarily diarrhea.

In a series of 25 patients with pancreatic and bile duct cancers (68% unresectable), Milano (2004) reported that 24 were treated with IMRT and concurrent 5-FU, one refused chemotherapy.<sup>[59]</sup> Resected patients received 45–50.4 Gy to the PTV, whereas unresectable patients received 50.4–59.4 Gy. For all cancers, the median OS was 13.4 months, with one- and two-year OS of 55% and 22%, respectively. One- and two-year median OS were 83% and 50%, respectively, among resected cases, and 40% and 8%, respectively, among unresected cases. IMRT was well tolerated, with grade 2 or less acute upper GI toxicity in 80% of patients; grade 4 late liver toxicity was reported in one patient who survived more than five years.

Ben-Joseph (2004) reported on a retrospective series that described the experience of 15 patients with pancreatic adenocarcinoma (seven resected, eight unresectable) who underwent IMRT plus concurrent capecitabine.<sup>[60]</sup> Resected cases received 45 to 54 Gy to the gross tumor volume, unresected cases received 54 to 55 Gy to the gross tumor volume; all cases received 45 Gy to the draining lymph node basin. At a median follow-up of 8.5 months, no deaths were reported among the resected patients, compared to two deaths in the unresected cases, yielding a one-year OS rate of 69% among the latter. No grade 4 toxicities were reported, with the vast majority of acute toxicities reported at grade 1 (nausea, vomiting, diarrhea, neutropenia, anemia).



A small nonrandomized comparative study reported the difference in the rates of acute GI toxicity between pancreatic/ampullary cancer patients treated with concurrent chemotherapy and either IMRT or 3D CRT.<sup>[61]</sup> The design relied on historical controls. There was a significant decrease in upper and lower GI toxicity (nausea, vomiting, diarrhea) in the IMRT-treated group. There was no significant difference in grade 3 to 4 weight loss among two groups of patients.

Additional, small case series studies continue to be published<sup>[62, 63]</sup>; however, large comparative studies are needed in order to draw conclusions about the efficacy and safety of IMRT for the treatment of pancreatic tumors.

## **GYNECOLOGIC CANCERS**

### **Systematic Review**

Lin (2018) completed a meta-analysis of six studies that enrolled a total of 1,008 subjects in order to compare the efficacy and safety of IMRT with 3D-CRT or 2D-RT for definitive treatment of cervical cancer.<sup>[64]</sup> Results revealed a nonsignificant difference in three-year OS (OR, 2.41; 95% CI, 0.62 to 9.39;  $p=0.21$ ) and disease-free survival rates (OR, 1.44; 95% CI, 0.69 to 3.01;  $p=0.33$ ) between IMRT and 3D-CRT or 2D-RT. However, IMRT was associated with a significantly reduced rate of acute GI and genitourinary (GU) toxicity: Grade 2 GI: OR, 0.5; 95% CI, 0.28 to 0.89;  $p=0.02$ ; Grade 3 or higher GI: OR, 0.55; 95% CI, 0.32 to 0.95;  $p=0.03$ ; Grade 2 GU: OR, 0.41; 95% CI, 0.2 to 0.84;  $p=0.01$ ; Grade 3 or higher GU: OR, 0.31; 95% CI, 0.14 to 0.67;  $p=0.003$ . Some chronic GU toxicity also occurred less frequently with IMRT (Grade 3: OR, 0.09; 95% CI, 0.01 to 0.67;  $p=0.02$ ). This analysis had several limitations including the fact that most included studies had relatively small sample sizes and were retrospective and nonrandomized in nature. Additionally, some of the included studies did not compare clinical outcomes between the RT techniques.

### **Randomized Controlled Trials**

Chopra (2021) conducted the open-label, parallel-group, randomized, phase 3, Postoperative Adjuvant Radiation in Cervical Cancer (PARCER) trial in order to evaluate whether postoperative image-guided IMRT was associated with an improvement in late GI toxicity compared to 3D-CRT.<sup>[65]</sup> In PARCER, 300 patients with cervical cancer and an indication for adjuvant postoperative RT were randomly assigned to image-guided IMRT ( $n=151$ ) or 3D-CRT ( $n=149$ ), with a median follow-up of 46 months (interquartile range, 20 to 72 months). Results revealed significantly fewer primary endpoint events (i.e., grade  $\geq 2$  late GI toxicity) in the image-guided IMRT arm versus the 3D-CRT arm (29 vs. 54). The three-year cumulative incidence of grade  $\geq 2$  late GI toxicity was significantly reduced in the IMRT arm (21.1% vs. 42.4%; hazard ratio [HR], 0.46; 95% CI 0.29 to 0.73;  $p<0.001$ ) as was the cumulative incidence of three-year grade  $\geq 3$  late GI toxicity (2.9% vs. 15.5%; HR, 0.22; 95% CI 0.08 to 0.59;  $p<.003$ ). The cumulative incidence of grade  $\geq 2$  any late toxicity was also significantly reduced with IMRT (28.1% vs. 48.9%; HR, 0.50; 95% CI 0.33 to 0.76;  $p<0.001$ ). Patients administered IMRT reported less diarrhea ( $p=0.04$ ), improvement in appetite ( $p=0.008$ ), and fewer bowel symptoms ( $p=0.002$ ) compared to those administered 3D-CRT. No differences in disease outcomes were noted between the RT techniques including three-year pelvic relapse-free survival ( $p=0.55$ ) and disease-free survival ( $p=0.89$ ).

In the international, randomized, PORTEC-3 trial, patients were randomized to receive pelvic radiotherapy alone or in combination with chemotherapy. Using data from this trial, Wortman

(2021) evaluated whether IMRT compared to 3D-CRT resulted in fewer adverse events and patient-reported symptoms among 658 patients with high-risk endometrial cancer.<sup>[66]</sup> Of these patients, 559 received 3D-CRT and 99 received IMRT; median follow-up at the time of analysis was 74.6 months. Results revealed no significant differences in frequency and grades of adverse events between the RT techniques. There was an increase in grade  $\geq 3$  adverse events (mainly GI and hematologic) with 3D-CRT (37.7% vs. 26.3%;  $p=0.03$ ). During follow-up, significantly more grade  $\geq 2$  diarrhea (15.4% vs. 4%;  $p<0.01$ ) and grade  $\geq 2$  hematologic adverse events (26.1% vs. 13.1%;  $p<0.01$ ) were observed in patients administered 3D-CRT as compared to IMRT. More patients reported diarrhea (37.5% vs. 28.6%;  $p=0.125$ ), bowel urgency (22.1% vs. 10%;  $p=0.0039$ ), and abdominal cramps (18.2% vs. 8.6%;  $p=0.058$ ) following 3D-CRT as compared to IMRT.

Klopp (2018) compared patient-reported acute toxicity in women with cervical and endometrial cancer treated with adjuvant radiotherapy after hysterectomy with IMRT or standard four-field radiation therapy.<sup>[67]</sup> The 278 eligible patients were randomly assigned to IMRT or standard RT. Patient-reported acute GI toxicity was measured with the bowel domain of the Expanded Prostate Cancer Index Composite (EPIC). Between baseline and the end of RT, the mean EPIC bowel, urinary, and Trial Outcome Index scores declined by 18.6, 5.6, and 8.8 points, respectively, in the IMRT group, and 23.6, 10.4, and 12.8 points, respectively, in the standard RT group. Statistically significant changes in EPIC bowel and urinary scores were reported at three and five weeks of RT, but not at four to six weeks post-RT.

A 2016 trial by Naik randomized 40 patients with cervical cancer to IMRT or to 3D-CRT.<sup>[68]</sup> Patients were included if they had not undergone any prior treatment, including hysterectomy. Both arms received concurrent radiation with cisplatin and 50 Gy at 25 fractions of RT. Dosimetric planning showed higher conformality and lower doses to organs at risk with IMRT. With follow-up through 90 days after treatment, vomiting and acute GI and genitourinary (GU) toxicity were significantly higher in the 3D-CRT group (see Table 3).

**Table 3. Acute Toxicity Grade 2 or Greater**

Toxicity	3D-CRT, n (%)	IMRT, n (%)	95% CI for the Difference	p
Hematologic	8 (40%)	7 (35%)	-0.219 to 0.119	0.644
Leucopenia	3 (15%)	2 (10%)	-0.1479 to 0.479	0.424
Vomiting	7 (35%)	3 (15%)	0.338 to 0.061	0.007
Acute gastrointestinal toxicity	9 (45%)	4 (20%)	-0.408 to -0.091	0.003
Acute genitourinary toxicity	7 (35%)	4 (20%)	-0.295 to -0.004	0.058

CI: confidence interval; IMRT: intensity-modulated radiotherapy; 3D-CRT: three-dimensional conformal radiation

Ghandi (2013) reported on a prospective randomized study that compared whole-pelvic IMRT with whole pelvic CRT as definitive therapy in 44 patients with locally advanced cervical cancer.<sup>[69]</sup> Each treatment arm had 22 patients. OS at 27 months was 87.7% with IMRT versus 76% with CRT ( $p=0.645$ ). However, fewer grade  $\geq 2$  and  $\geq 3$  GI toxicities were experienced in the IMRT group than the CRT group.

Yu (2015) compared outcomes of IMRT and 3D-CRT combined with concurrent chemotherapy for the definitive treatment of cervical cancer.<sup>[70]</sup> A total of 72 patients with Grades IIa to IIIb

cervical cancer were randomly assigned to receive IMRT or 3D-CRT along with concurrent chemotherapy with nedaplatin. No statistically significant differences in overall survival or disease-free survival were reported in the three years of follow-up. Grade III diarrhea was significantly different between groups, at 5.6% in the IMRT group and 30.6% in the 3D-CRT group.

## Nonrandomized Studies

Zhang (2020) reported on a study of IMRT-based concurrent chemoradiotherapy with Endostar, a modified recombinant human endostatin, for cervical cancer. This phase 2 study included 31 patients with pelvic locoregional recurrence of cervical cancer following surgery treated with IMRT-based concurrent chemotherapy.<sup>[71]</sup> The objective response rate was 67.74%. Response was complete in 48.39% and partial in 19.35%, with a 16.13% rate of disease stabilization, and 16.13% rate of progressive disease. Overall, the disease control rate was 83.87%. The most commonly reported adverse events were nausea, vomiting, alopecia, neutropenia, and leukopenia, mostly grade 1 or 2. Grade 3 thrombocytopenia and neutropenia were reported in two patients each, and leukopenia in 4 patients. No grade 4 acute toxicities were reported.

A retrospective study by Contreras (2020) of 53 cervical cancer patients with 70-month follow-up reported outcomes following radical hysterectomy, lymphadenectomy, and post-operative IMRT and high dose rate brachytherapy.<sup>[72]</sup> Clinical stages were IB1 (n=19), IB2 (n=7), IIB (n=7), IIIC1 (n=19), and IIIC2 (n=1). Five-year actuarial rates for regional nodal failure, distant failure outside the radiation field, any failure, and overall survival were 11%, 11%, 14%, and 85%, respectively.

Yamamoto (2020) performed a retrospective study of the efficacy of IMRT for postoperative cervical cancer.<sup>[73]</sup> A total of 62 patients were included, 36 of whom received chemotherapy. During the median follow-up period of 50.9 months, there was no locoregional failure. Six of 35 patients with high-risk prognostic factors relapsed, but none of the 27 patients with intermediate-risk prognostic factors relapsed ( $p=0.02$ ). The three-year OS and relapse free survival rates were 98.2% and 90.9%, respectively.

Vavassori (2019) reported on outcomes of 50 patients with stages IB1 to IVB cervical cancer treated with IMRT followed by pulsed-dose-rate brachytherapy exclusively (no prior treatment) for cervical cancer.<sup>[74]</sup> Median follow-up was 33 months. The one- and five-year progression-free survival were 83% (95% CI 69 to 91%) and 76% (95% CI 61 to 86%), and the three- and five-year overall survival were 91% (95% CI 78 to 97%) and 76% (95% CI 56 to 88%), respectively. Urinary and rectal toxicity higher than grade 2 was observed in 6.3% and 17% of patients, respectively, and five patients (10.6%) had grade 4 gastrointestinal toxicity requiring colostomy.

In a prospective study of 35 patients, Mell (2020) reported results of a nonrandomized prospective dose escalation trial.<sup>[75]</sup> Patients with stage IB to IVA cervical cancer with either an intact cervix or posthysterectomy with residual/recurrent pelvic or paraortic nodal involvement were treated with image guided IMRT and five cycles of concurrent weekly cisplatin (40mg/m<sup>2</sup>) with escalating doses of gemcitabine. Analysis of the 35 patients indicated that a higher maximum tolerated dose of chemotherapy than previously reported studies that used less conformal radiation techniques was feasible in this treatment regimen using image guided IMRT.

Chen (2020) performed a retrospective review of 161 stage III endometrial cancer patients, 154 of whom received adjuvant therapy.<sup>[76]</sup> Adjuvant therapies included chemotherapy alone (42%), adjuvant radiotherapy with IMRT or VMAT alone (18%), and chemoradiotherapy (36%). On univariate analysis, the variables that were associated with differences in outcomes were older age (associated with increased risk of tumor recurrence;  $p=0.008$ ), non-endometrioid histology and grade 3 tumor status (associated with increased risk of tumor recurrence and death;  $p<0.001$ ), and adjuvant radiotherapy alone or in combination with chemotherapy (longer five-year RFS;  $p=0.046$ ). Patients who received adjuvant chemotherapy alone or chemotherapy plus radiotherapy showed similar five-year OS and RFS to those that did not receive any chemotherapy (OS  $p=0.965$ , RFS  $p=0.836$ ).

In an analysis of medical records from 114 patients, Kumar (2019) reviewed the relationship between dose to pelvic bone marrow and hematological toxicity in cervical cancer patients.<sup>[77]</sup> 75.4% were treated with 3D radiation therapy and 24.6% received IMRT. Results of a univariate analysis showed more frequent grade 3+ leukopenia in the IMRT group (OR 3.5; 95% CI 1.4 to 9.1;  $p=0.007$ ). The authors noted that bone marrow was not treated as an OAR in these patients, and suggested dose constraints for the lower pelvis, pelvic bone, and iliac crests.

Lin (2019) reported long-term outcomes in patients treated IMRT and 3D image-guided adapted brachytherapy compared to those treated with 2D EBRT and 2D brachytherapy.<sup>[64]</sup> Patients treated before 2005 received 2D therapy while patients treated 2005 to 2013 were treated with IMRT/3D therapy. There were 300 patients per treatment group. The median follow-up for patients alive at the time of last follow-up was 15.3 years in the 2D group and 7 years in the IMRT/3D group. The five-year freedom from relapse, cancer-specific survival, and OS were 57, 62, and 57%, respectively, in the 2D group and 65, 69, and 61%, respectively, in the IMRT/3D group.

Lei (2019) reported noncomparative outcomes and toxicity in patients treated with IMRT along with intracavitary brachytherapy and concurrent chemotherapy.<sup>[78]</sup> A total of 108 patients were treated, of whom 45 were stage IIB and 63 were stage IIIB. The five-year cumulative incidence of pelvic failure alone, OS rate, and PFS rate were 8.3, 67.6, and 53.7%, respectively. The five-year cumulative incidences of grade 3 or greater acute leukopenia and late gastrointestinal and genitourinary toxicities were 51.8 and 9.2%, respectively.

In 2016, Shih reported a retrospective comparison of bowel obstruction following IMRT ( $n=120$ ) or 3D-CRT ( $n=104$ ) after hysterectomy for endometrial or cervical cancer.<sup>[79]</sup> Groups were generally comparable, except more patients in the 3D-CRT group had open hysterectomy (81% vs 47%,  $p<0.001$ ). Patients received regular examinations throughout a median follow-up of 67 months, and the five-year rate of bowel obstruction was 0.9% in the IMRT group compared with 9.3% for 3D-CRT ( $p=0.006$ ). A body mass index of 30 kg/m<sup>2</sup> or more was also associated with less bowel obstruction. However, on multivariate analysis the only significant predictor of less bowel obstruction was IMRT ( $p=0.022$ ).

A series of reports from a single institution provided data on clinical outcomes achieved with IMRT in women with gynecologic malignancies. Patients from an initial series<sup>[80]</sup> were included in a subsequent report that comprised 40 patients who underwent IMRT to treat cancers of the cervix, endometrium, and other sites.<sup>[81]</sup> Patients in this series underwent postsurgical IMRT (70%), with (58%) or without (42%) cisplatin chemotherapy, with a majority (60%) also undergoing postradiotherapy intracavitary brachytherapy (ICB). IMRT was prescribed to the

PTV at a dose of 45 Gy, delivered in 1.8 Gy daily fractions; ICB delivered an additional 30–40 Gy to cervical cancer patients and 20–25 Gy to those with endometrial cancer. A well-matched nonconcurrent cohort of patients who underwent four-field CRT (45 Gy to the PTV, 1.8 Gy daily fractions) using 3D planning and received cisplatin chemotherapy was used to compare acute GI and genitourinary (GU) toxicities between radiotherapy modalities. No grade 3 acute GI or GU toxicities were reported in IMRT or CRT recipients. Grade two GI toxicity was noted in 60% of the IMRT cohort versus 91% of the CRT group ( $p=0.002$ ). No significant differences were noted in the incidence of grade 2 GU toxicity in IMRT recipients (10%) compared to the CRT cohort (20%).

Three other reports from the same group provide data on acute hematologic toxicity<sup>[82]</sup>, chronic GI toxicities<sup>[83]</sup>, and acute GI toxicities<sup>[84]</sup> among patients who underwent IMRT with or without chemotherapy. It is unclear whether or not the patients in these reports are those from the initial studies or are new patients. These and other studies<sup>[85, 86]</sup> suggest that the use of IMRT is associated with a low incidence of severe toxicities, although mild-to-moderate adverse effects were reported.

Two subsequent studies examined the use of post-hysterectomy radiotherapy in women with high-risk cervical cancer. In the first study, 68 patients were treated with adjuvant pelvic radiotherapy, high dose-rate ICB, and concurrent chemotherapy.<sup>[87]</sup> The initial 35 cases received four-field box CRT delivered to the whole pelvis; a subsequent 33 patients underwent IMRT. All patients received 50.4 Gy of radiation in 28 fractions and six Gy of high dose-rate vaginal cuff ICB in three insertions; cisplatin was administered concurrently to all patients. All patients completed the planned course of treatment. At median follow-up of 34.6 months (range: 12 to 52 months) in CRT recipients and 14 months (range: 6 to 25 months) in IMRT recipients, the one-year locoregional control rate was 94% for CRT and 93% for IMRT. Grades 1 to 2 acute GI toxicities were noted in 36% and 80% of IMRT and CRT recipients, respectively ( $p=0.00012$ ), while acute grade 1 to 2 GU toxicities occurred in 30% versus 60%, respectively ( $p=0.022$ ). There was no significant difference between IMRT and CRT in the incidence of acute hematologic toxicities. Overall, the IMRT patients had lower rates of chronic GI ( $p=0.002$ ) toxicities than the CRT patients.

A subsequent report from the same group included the initial 33 patients in that experience with an additional 21 cases.<sup>[88]</sup> At a median follow-up of 20 months, this study showed a three-year disease-free survival rate of 78% and an OS rate of 98% in IMRT recipients.

In 2014, Chen reported on 101 patients with endometrial cancer treated with hysterectomy and adjuvant radiotherapy.<sup>[89]</sup> No significant differences between IMRT patients ( $n=65$ ) and CRT patients ( $n=36$ ) were found in five-year OS, local failure-free survival, and DFS (82.9% vs 93.5% [ $p=0.26$ ]; 93.7% vs 89.3% [ $p=0.68$ ]; 88.0% vs 82.8% [ $p=0.83$ ], respectively). However, the IMRT patients experienced less acute and late toxicities.

Shih (2013) reported the results on 46 patients who received IMRT after hysterectomy and bilateral salpingo-oophorectomy for endometrial cancer, 78% of whom had stage III disease.<sup>[90]</sup> At a median of 52 months of follow-up, five-year OS was 90% while toxicities were minimal.

Beriwal (2013) reported on 42 patients treated for locally advanced vulvar carcinoma with IMRT and chemotherapy.<sup>[91]</sup> Sixteen (48.5%) patients had complete pathologic response and 15 remained progression-free at a median of 26.5 months. Eight patients developed recurrence at the surgical site of the vulva. Chronic grade 3 or higher GI or GU toxicity did not occur.

A small case series (Hsieh 2009) involved 10 patients who underwent IMRT with intracavitary brachytherapy boost for locally advanced (FIGO stage IIB and IIIB) cervical cancer.<sup>[92]</sup> During radiotherapy, all patients received cisplatin. Whole pelvic IMRT was administered to a dose of 50.4 Gy in 28 fractions, and intracavitary brachytherapy was delivered to a dose of 30 Gy in six fractions. The mean OS was 25 months (range 3 to 27 months), with actuarial OS of 67%. Acute toxicities included one patient with grade 3 diarrhea, one with grade 3 thrombocytopenia, and three with grade 3 leukopenia. One case of subacute grade 3 thrombocytopenia was noted.

Additional publications of IMRT for gynecologic cancer consist of small case series<sup>[69, 93-104]</sup> and non-randomized comparative studies<sup>[102, 103, 105-108]</sup> that continue to report favorable outcomes with IMRT treatment in patients with different types of gynecologic cancers (cervical, ovarian, endometrial).

## PROSTATE CANCER

### Primary (Definitive) Therapy for Localized Prostate Cancer

#### Systematic Reviews

In order to understand the impact of IMRT as definitive therapy for localized prostate cancer, well-designed randomized controlled trials (RCTs) are preferred. However, these are often difficult to perform given the populations involved. Therefore, this evidence section includes systematic reviews and meta-analyses of nonrandomized studies.

A 2016 meta-analysis by Yu included 23 studies (total n=9,556 patients) that compared IMRT with 3D-CRT for gastrointestinal (GI), genitourinary (GU), and rectal toxicity, biochemical control, and overall survival (OS).<sup>[109]</sup> The meta-analysis included 16 retrospective comparisons and five prospective cohort studies published before July 2015. The relative risk for the pooled analysis was considered significant if the 95% confidence interval did not overlap at the p<0.05 level. IMRT resulted in less acute and late GI toxicity, less rectal bleeding, and improved biochemical control (see Table 4). There was a modest increase in acute GU toxicity, and no significant differences between the two treatments in acute rectal toxicity, late GU toxicity, and OS.

**Table 4. Outcomes for IMRT Compared With 3D-CRT**

Comparison	No. of Studies	No. of Patients	RR IMRT vs 3D-CRT	95% CI
Acute GI toxicity	12	4142	0.59	0.44 to 0.78
Late GI toxicity	13	6519	0.54	0.38 to 0.78
Acute rectal toxicity	4	2188	1.03	0.45 to 2.36
Late rectal bleeding	5	1972	0.48	0.27 to 0.85
Acute GU toxicity	14	4603	1.08	1.00 to 1.17
Late GU toxicity	14	5608	1.03	0.82 to 1.30
Biochemical control	6	2416	1.17	1.08 to 1.27
Overall survival	3	924	1.07	0.96 to 1.19

CI: confidence interval; GI: gastrointestinal, grade two to four toxicity; GU: genitourinary, grade two to four toxicity; IMRT: intensity modulated radiotherapy; No.: number; RR: relative risk; 3D-CRT: three-dimensional conformal radiotherapy.

In 2012, Bauman published a systematic review that examined the evidence for IMRT in the treatment of prostate cancer to quantify its potential benefits and to make recommendations for radiation treatment programs considering adopting this technique within the province of Ontario, Canada.<sup>[110]</sup> Based on a review of 11 published reports through March 2009 (nine retrospective cohort studies and two randomized clinical trials [RCTs]) including 4559 patients, the authors put forth the recommendation for IMRT over 3D-CRT for aggressive treatment of localized prostate cancer where an escalated radiation (>70 gray [Gy]) dose is required. There were insufficient data to recommend IMRT over 3D-CRT in the postoperative setting.

Nine of 11 studies reviewed by Bauman reported on adverse effects. Six of nine studies reported on acute gastrointestinal (GI) effects. Four studies (three retrospective cohort studies, one RCT) reported differences in adverse effects between IMRT and 3D-CRT. The RCT included a total of 78 patients and reported that acute GI toxicity was significantly less frequent in the IMRT group compared with 3D-CRT. This was true for grade two or higher toxicities (20% vs 61%,  $p=0.001$ ), grade three or higher toxicity (0 vs 13%,  $p=0.001$ ) and for acute proctitis (15% vs 38%,  $p=0.03$ ). In contrast, the second RCT included in this systematic review reported that there were no differences in toxicity between IMRT and 3D-CRT.

Six of nine studies reported on acute genitourinary (GU) effects. One study, which was a retrospective cohort study including 1571 patients, reported a difference in overall acute GU effects in favor of 3D-CRT (37% IMRT vs 22% 3D-CRT,  $p=0.001$ ). For late GI toxicity, four of nine studies, all retrospective cohort studies with a total of 3333 patients, reported differences between IMRT and 3D-CRT. One RCT reported on late GI toxicity and did not find any differences between IMRT and 3D-CRT. Five of nine studies reported on late GU effects, and only one reported a difference in late GU effects in favor of 3D-CRT (20% vs 12%,  $p=0.01$ ). Two retrospective cohort studies reported mixed findings on quality-of-life outcomes. A subsequent economic analysis (based on this systematic review data) demonstrated that for radical radiation treatment (>70 Gy) of prostate cancer, IMRT seems to be cost-effective when compared with an equivalent dose of 3D-CRT from the perspective of the Canadian health care system for 2009.<sup>[111]</sup>

In 2008, the Agency for Healthcare Research and Quality (AHRQ) published a systematic review comparing the relative effectiveness and safety of various treatment options for clinically localized prostate cancer.<sup>[112]</sup> Studies on IMRT were included in the assessment under the category of external beam radiotherapy (EBRT). Based on review of RCTs and nonrandomized studies published from 2000 to September 2007, there was no direct evidence (i.e., from RCTs) that IMRT resulted in better survival or disease-free survival (DFS) than other therapies for localized prostate cancer. Based on case-series data, the absolute risks of clinical and biochemical outcomes (including tumor recurrence), toxicity, and quality of life after IMRT were comparable with conformal radiation. For IMRT, the percent of patients with grade one and two acute GI toxicity was 22% and 4%, respectively; the percent of patients with rectal bleeding was 1.6% to 10%; and the percent of patients with grade two GU toxicity was 28% to 31%. This review concluded that there was low-level evidence that IMRT provides at least as good a radiation dose to the prostate with less radiation to the surrounding tissues compared with CRT.<sup>[112]</sup>

In 2010, an update of the 2008 AHRQ systematic review was undertaken by the AHRQ Technology Assessment Program.<sup>[113]</sup> As with the 2008 review, this review concluded that the available data were insufficient to compare the effectiveness of the various forms of radiation treatments. Studies on IMRT were included in the assessment under the category of EBRT

and thus reported data were not specific to IMRT. While higher EBRT dosages may result in longer-term biochemical control than lower EBRT dosages, overall and disease-specific survival data were inconclusive. Additionally, GU and GI toxicities experienced with EBRT did not seem to differ when standard fractionation was compared with moderate hypofractionization. The authors noted the need for further studies to evaluate outcomes of IMRT for the treatment of prostate cancer.<sup>[113]</sup> In addition, a subsequent report was undertaken by the AHRQ Comparative Effectiveness Review Surveillance Program using the search strategy employed for the 2008 systematic review in 2014.<sup>[114]</sup>

Similar findings were observed in a systematic review by Hummell of the clinical effectiveness of IMRT for the radical treatment of prostate cancer undertaken by the U.K. Health Technology Assessment Programme in 2010.<sup>[115]</sup> The literature search was through May 2009, from which eight full-length, non-randomized studies of IMRT versus 3D-CRT were identified. Clinical outcomes were overall survival, biochemical (PSA) relapse-free survival, toxicity, and health-related quality of life. The biochemical relapse-free survival was not affected by treatment received, except when there was a dose difference between groups; in these cases a higher dose with IMRT was favored over lower doses with 3D-CRT. There was some indication that genitourinary toxicity was worse for patients treated with dose escalated IMRT, however, any group difference resolved by six months after treatment. Comparative data of IMRT versus 3D-CRT seem to support the theory that higher doses, up to 81 Gy, can improve biochemical survival for patients with localized prostate cancer, concurring with data on 3D-CRT. Most studies reported an advantage for IMRT in GI toxicity, particularly with regard to the volume of the rectum treated, as toxicity can be reduced by increasing conformality of treatment, which can be more easily achieved with IMRT than 3D-CRT.

### Therapy for Prostate Cancer after Prostatectomy

Leite (2021) conducted a single-arm, phase 2 study that evaluated the safety and feasibility of postoperative hypofractionated RT with intensity-modulated and image-guided RT to the prostate bed in 61 patients who had undergone radical prostatectomy.<sup>[116]</sup> Of these patients, 57 received salvage RT and four received adjuvant RT. The dose prescribed to the prostate bed was 51 Gy in 3.4 Gy daily fractions using IMRT and imaging guidance; all patients were treated with IMRT with volumetric arch therapy. After a median follow-up of 16 months, results revealed that 11.5% of patients experienced acute grade  $\geq 2$  GU symptoms and 13.1% experienced acute grade  $\geq 2$  GI symptoms. Late grade  $\geq 2$  GU and GI toxicity occurred at a rate of 8.2% and 11.5%, respectively. Three patients experienced a biochemical recurrence and the median time to the PSA nadir was nine months.

Flores-Balcázar (2020) compared 3D-CRT and IMRT/VMAT for post-radical prostatectomy radiation therapy. Of the 83 total patients, 30 received 3D-CRT, and 53 received IMRT/VMAT. Rates of acute GU toxicity for IMRT/VMAT- and 3D-CRT-treated patients were 9.4% and 13.3% ( $p = 0.583$ ), respectively, while five-year actuarial rates of late GI toxicity were 1.9% and 6.7%, for the same groups respectively. Rates of late GU toxicity for IMRT/VMAT- and 3D-CRT-treated patients were 7.5% and 16.6% ( $p=0.199$ ), respectively. No significant differences were identified between groups.

In 2014, initial results of the PLATIN three trial (Prostate and Lymph Node Irradiation with Integrated-Boost- IMRT after Neoadjuvant Antihormonal Treatment) were published.<sup>[117]</sup> This phase two trial evaluated the safety and feasibility of irradiation of the pelvic lymph nodes simultaneously with a boost to the prostate bed. From 2009 to 2011, 40 patients with high-risk



features or inadequate lymphadenectomy after RP were enrolled; 39 patients finished the treatment. Treatment consisted of two months of antihormonal treatment before IMRT of the pelvic lymph nodes (51.0 Gy) with a simultaneous integrated boost to the prostate bed (68.0 Gy). No acute grade three or four toxicity occurred. 22.5% of patients experienced acute grade two GI and GU toxicity and 10% late grade two GI and 5% late grade two GU toxicity. One patient developed late grade three proctitis and enteritis. After a median of 24 months, 89% of patients were free of a PSA recurrence.

In 2014, acute toxicity results from the PRIAMOS1 (Hypofractionated Radiotherapy of the Prostate Bed With or Without the Pelvic Lymph Nodes) trial were reported.<sup>[118]</sup> This prospective phase two trial assessed safety and toxicity of hypofractionated RT of the prostate bed with IMRT as a basis for further prospective trials. Forty patients with indications for adjuvant or salvage therapy (pathologic stage T3 and/or R1/2 or with a PSA recurrence after prostatectomy) were enrolled from February to September 2012; 39 were evaluated. All patients received a total dose of 54.0 Gy to the prostate bed, 28 for salvage and 11 in the adjuvant setting. Based on preoperative staging, patients were risk stratified as low (n=2), intermediate (n=27), or high (n=10). Ten weeks after completion of therapy, there were no adverse events grade three or greater. Acute GI toxicity rates were 56.4% and 17.9% for grade one and two, respectively, and acute GU toxicity was recorded in 35.9% of patients at a maximum grade of one.

In 2013, Corbin reported adverse effects in high-risk men two years after IMRT post-prostatectomy.<sup>[119]</sup> Between 2007 and 2010, 78 consecutive men received either adjuvant RT (n=17 [22%]) or salvage RT (n=61 [78%]). Median IMRT dose was 66.6 Gy (range, 60 to 72 Gy). Quality of life data were collected prospectively at 2, 6, 12, 18, and 24 months, and included urinary incontinence, irritation or obstruction, bowel or rectal function and sexual function. No significant changes were observed from baseline through two-year follow-up, with global urinary irritation or obstruction scores unchanged or improved over time from baseline, global urinary incontinence improved from baseline to 24 months in the subset of patients receiving adjuvant therapy, and global bowel and sexual domain scores lower at two months but improved or unaffected over follow-up.

In 2013, Massaccesi reported preliminary results of acute toxicities during a phase two trial of hypofractionated IMRT with simultaneous integrated boost (SIB) to the pelvic nodes and prostate bed after prostatectomy.<sup>[120]</sup> Between November 2008 and February 2012, 49 patients considered to be at high risk of relapse after RP or who had biochemical relapse received 45 Gy in 1.8 Gy fractions to the whole pelvis and 62.5 Gy, 2.5 Gy fractions (equivalent dose, 68.75) to the prostate bed. The toxicity findings were compared to those of 52 consecutive patients who underwent adjuvant or salvage 3D-CRT with standard 2 Gy fractionation to the prostatic bed and regional pelvic nodes who were selected from an electronic database. Grade one or greater acute GU toxicity occurred in 71.2% of all patients without a significant difference between the groups (hypofractionated IMRT vs conventionally fractionated 3D-CRT) (p=0.51). Grade two acute GU toxicity, reported in 19.8% of all patients, was less frequent in patients in the IMRT group (9.6% vs 28.8%, p=0.02). There were no cases of grade three acute GU toxicity. Thirty (29.7%) patients developed grade two acute GI toxicity; the difference between groups was not significant. No cases of grade three acute GI toxicity were reported. The authors concluded that the acute toxicity profile for hypofractionated high-dose SIB-IMRT in the post prostatectomy setting compares favorably with that of conventionally fractionated high-dose 3D-CRT.

A 2013 AUA/ASTRO guideline on the use of adjuvant and salvage RT after prostatectomy was based on a systematic review of the literature from 1990 to 2012, which yielded 294 articles.<sup>[121]</sup> The panel's comments on RT technique state that they attempted to determine which technique and doses produced optimal outcomes, but that it was not possible to answer these questions from available data, as the majority of the data come from observational studies and approximately one-third treated patients with conventional (2D) external beam modalities. Of the literature included in the review, less than 5% reported using IMRT. The panel stated that 64 to 65 Gy is the minimum dose that should be delivered after prostatectomy, but that this should be individualized to the patient.

Alongi 2009 reported the results of acute toxicity of whole-pelvis irradiation in 172 consecutive patients with clinically localized prostate cancer who were treated with either IMRT or 3D-CRT as adjuvant (n=100) or salvage (n=72) RT after radical prostatectomy and pelvic lymph node dissection.<sup>[122]</sup> Whole pelvis radiation was considered in patients with a limited lymphadenectomy and/or in the presence of a high-risk of nodal involvement, in patients with positive lymph nodes and/or in the presence of adverse prognostic factors (Gleason >7 and/or preoperative PSA >10 ng/mL). Eighty-one patients underwent 3D-CRT and 91 underwent IMRT. No grade three or higher acute GU or lower GI side effects were observed. Acute grade two GU occurred in 10 (12.3%) of 81 of the 3D-CRT group and in 6 (6.6%) of 91 of the IMRT group (p=0.19). For acute lower GI grade two events, the incidence was 7 (8.6%) of 81 in the 3D-CRT group versus 3 of 91 (3.3%) in IMRT (p=0.14) group. Acute upper GI grade two or higher toxicities were 18 of 81 (22.2%) of 81 and 6 of 91 (6.6%) of 91 in 3D-CRT and IMRT group, respectively (p=0.004). The authors concluded that acute toxicity following postoperative whole pelvis irradiation was reduced with the use of IMRT as compared to 3D-CRT; this effect was most significant for upper GI symptoms, owing mainly to better bowel sparing with IMRT.

### Hypofractionation

Men with either localized, or locally advanced prostate cancer have historically been treated with either radical prostatectomy or external beam irradiation +/- ADT. Patients opting for irradiation treatment have historically received such treatment via "conventional" fractionation patterns involving small daily doses of 1.8 to 2.0 Gy for a total of 35 to 45 treatment fractions over seven to nine weeks. Appreciation of the low cell survival Alpha/Beta ratio following irradiation of prostate cancer cells, compared to cells of surrounding organs at risk, has prompted interest in "hypofractionated" approaches. Via such approaches, fewer fractions of higher daily doses of irradiation are provided. Hypofractionation is expected to result in improvement in the overall therapeutic ratio while reducing health care cost, improving patient convenience and increasing efficacy of clinic practice.

A 2019 Cochrane systematic review assessed the safety and effectiveness of hypofractionation (fewer, larger doses of daily radiation) compared to conventional fractionation for the treatment of clinically localized prostate cancer.<sup>[123]</sup> A total of 10 randomized controlled trials including 8,278 subjects met inclusion criteria. Little or no difference between hypofractionation and conventional fractionation was indicated by the data for prostate cancer-specific survival (HR 1.00, 95% CI 0.72 to 1.39; low-certainty evidence), late radiation therapy genitourinary (GU) toxicity (RR 1.05, 95% CI 0.93 to 1.18; moderate-certainty evidence), overall survival (HR 0.94, 95% CI 0.83 to 1.07; high-certainty evidence), metastasis-free survival (HR 1.07, 95% CI 0.65 to 1.76; low-certainty evidence), and acute GU radiation therapy toxicity (RR 1.03, 95% CI 0.95 to 1.11; moderate-certainty evidence). It was

unclear whether there was a difference in fractionation schedules on late radiation therapy gastrointestinal (GI) toxicity (RR 1.10, 95% CI 0.68 to 1.78; very low-certainty evidence). The analysis did identify a difference between groups in biochemical recurrence-free survival based on Phoenix criteria (HR 0.88, 95% CI 0.68 to 1.13; moderate-certainty evidence), but this was reported to be small and possibly unimportant. Overall, the authors concluded that moderate hypofractionation (up to a fraction size of 3.4 Gy) results in similar oncologic outcomes in terms of disease-specific, metastasis-free and overall survival.

## **ANAL CANCER**

Recent studies have found IMRT with chemotherapy for the treatment of anal cancer reduces acute and late adverse events compared with 3D-CRT with chemotherapy. This raises the possibility of increasing dose to the target tissue without increasing adverse events. However, survival outcomes have not differed significantly between IMRT and CRT, and concerns exist over increases in locoregional recurrence with IMRT.

### **Randomized Controlled Trials**

One small (n=20) RCT on IMRT for the treatment of anal canal cancer was identified. In this publication from Rattan (2016), grade III GI toxicity during treatment was observed in 0% of patients in the IMRT group compared with 60% of patients treated with 3D-CRT (p=0.010).<sup>[124]</sup> Hematologic grade III toxicity was seen in 0% of patients treated with IMRT compared to 20% of patients treated with 3D-CRT (p=NS). Other parameters indicating better tolerance of treatment were reduced need for parenteral fluid (10% vs 60%, p=0.019) and blood transfusion (0% vs 20%, p=0.060).

### **Nonrandomized Comparative Studies**

Gul (2023) compared outcomes and factors associated with prognosis from 162 patients treated for anal cancer in Turkey between 1995 and 2019.<sup>[125]</sup> All patients were treated with radiotherapy and 140 had concurrent chemotherapy. Seventy patients received IMRT, 74 patients had 2-dimensional-3-dimensional (2D-3D) conformal therapy, and data were missing for 18 patients. At five years, overall survival (OS) was 75.1% and disease-specific survival was 76.4%. OS was significantly correlated with a radiation dose of 58 Gy or less (p = 0.006) and IMRT planning (p=0.008). Lower rates of acute and late radiation side effects were associated with IMRT (acute, p = 0.002; late, p = 0.001). Completing radiation therapy in fewer than 45 days (p= 0.013) and receiving concurrent chemotherapy (p = 0.0003) were also associated with longer survival. The study suggests IMRT is superior to 2D-3D conformal therapy, but was limited by its retrospective design and treatment heterogeneity.

Vendrely (2023) published an observational cohort study to evaluate clinical practices, treatments, patient outcomes and prognostic factors on all cases of non-metastatic squamous cell anal cancer treated at 60 French centers from 2015 to 2020.<sup>[126]</sup> The study included 1015 patients, of whom 815 were treated with IMRT. Treatment interruption was more common in people treated with conformal 3D RT than IMRT (65.4% vs. 39.6%; p=0.0006). IMRT was also positively associated with colostomy-free survival (CFS) in those with locally advanced disease, but the difference was not significant (0.066).

Sauter (2020) reported outcomes following IMRT and 3D-CRT in 82 patients with newly diagnosed anal carcinoma.<sup>[127]</sup> At one year following treatment, of the 40 patients treated with IMRT, 39 were in complete remission and of the 39 patients treated with 3D-CRT, 31 were in

complete remission ( $p=0.014$ ). Tumor T stage and lack of IMRT treatment were identified by multivariate analysis as risk factors for persistent tumor at six months. The IMRT group had significantly lower skin toxicity ( $p=0.00092$ ).

In a retrospective review of 89 consecutive patients (52 IMRT, 37 3D-CRT), Chuong (2013) found three-year OS, progression free survival, locoregional control, and colostomy-free survival did not differ significantly in patients treated with IMRT compared with 3D-CRT ( $p>0.1$ ).<sup>[128]</sup> Adverse events with 3D-CRT were more frequent and severe, and required more treatment breaks than IMRT (11 vs 4;  $p=0.006$ ) even though the median duration of treatment breaks did not differ significantly (12.2 days vs 8.0 days;  $p=0.35$ ). IMRT patients had fewer acute grade 3 or higher nonhematologic toxicity ( $p=0.012$ ), and fewer acute grade 3 or higher skin toxicity.

Dewas (2012) retrospectively reviewed 51 patients with anal cancer treated with IMRT or 3D-CRT (24 IMRT, 27 3D-CRT).<sup>[129]</sup> Outcomes also did not differ significantly between IMRT and 3D-CRT for 2-year OS, locoregional relapse-free survival, and colostomy-free survival. Grade 3 acute toxicity occurred in 11 IMRT patients versus 10 3D-CRT patients.

Dasgupta (2013) retrospectively reviewed 223 patients (45 IMRT, 178 CRT) to compare outcomes in patients treated for anal cancer.<sup>[130]</sup> The authors reported that two-year OS, distant metastases-free survival, and locoregional recurrence-free survival did not differ significantly between IMRT and CRT. Milano (2005) published a single-institution series included 17 patients with stage I/II cancer who underwent IMRT alone ( $n=3$ ) or concurrent with 5FU alone ( $n=1$ ) or 5FU with mitomycin C (MMC,  $n=13$ ).<sup>[131]</sup> Patients generally received 45 Gy to the PTV at 1.8 Gy per fraction, followed by a 9 Gy boost to the GTV. Thirteen (76%) of 17 patients completed treatment as planned. None experienced acute or late grade 3 or above nonhematologic (GI or GU) toxicity. Grade 4 acute hematologic toxicity (leukopenia, neutropenia, thrombocytopenia) was reported in five (38%) of 13 patients who received concurrent chemoradiotherapy. At a median follow-up of 20.3 months, the two-year OS rate was 91%.

## **RECTAL CANCER**

### **Systematic Reviews**

Wee (2018) performed a systematic review of the literature comparing acute GI and GU toxicity profiles between IMRT and 3D-CRT in rectal cancer patients treated with neoadjuvant chemoradiation.<sup>[132]</sup> No significant heterogeneity or publication bias was detected in the six studies that met inclusion criteria. These studies, all of which were comparative and retrospective, included 859 patients. A subset of four to five of these studies were used in meta-analyses of grade  $\geq 2$  acute overall GI toxicity, diarrhea, proctitis, and overall GU toxicity. GI toxicity, diarrhea, and proctitis were significantly reduced in the IMRT group. In the meta-analysis of  $\geq 3$  overall GI toxicity, diarrhea, proctitis, and overall GU toxicity, only acute proctitis was found to be significantly reduced in the IMRT group. In the pooled analysis, the IMRT group was found to have significantly lower rates of every toxicity endpoint except for grade  $\geq 3$  overall GU toxicity. Limitations of this meta-analysis include the small number of studies included in meta-analysis for each endpoint and the retrospective nature of the included studies. In addition, this analysis did not address oncologic outcomes, which may be a concern given the possibility of missed target volume due to the sensitivity of IMRT to geometric uncertainties and organ motion.

## Nonrandomized Comparative Studies

In 2017, Sun reported an analysis of the National Cancer Data Base to compare IMRT with 3D-CRT for the treatment of rectal adenocarcinoma.<sup>[133]</sup> A total of 7386 patients with locally advanced rectal carcinoma were treated with neoadjuvant chemoradiotherapy (45-54 Gy) during the period from 2006 to 2013; 3330 (45%) received IMRT and 4065 (55%) received 3D-CRT. Use of IMRT increased from 24% in 2006 to 50% in 2013. Patient age, race, insurance status, Charlson-Deyo comorbidity score, hospital type, income and education status, and clinical stage of disease were not predictive of which RT was used. The mean radiation dose was higher with IMRT (4735 centigray vs 4608 centigray,  $p < 0.001$ ) and the occurrence of sphincter loss surgery was higher (see Table 5). Patients treated with IMRT also had higher risk of positive margins. Multivariate analysis found no significant differences between the treatments for pathologic downstaging, unplanned readmission, 30-day mortality, or long-term survival. This study used unplanned readmission as a surrogate measure of adverse events but could not assess acute or late toxicity.

**Table 5. Outcomes Following Radiochemotherapy with 3D-CRT or IMRT for Rectal Cancer**

Outcome	3D-CRT	IMRT	Adjusted OR	95% CI	p
Pathologic downstaging	57.0%	55.0%	0.89	0.79 to 1.01	0.051
Sphincter loss surgery	28.3%	34.7%	1.32	1.14 to 1.52	<0.001
Positive resection margin	5.6%	8.0%	1.57	1.21 to 2.03	<0.001
Unplanned readmission	7.9%	6.4%	0.79	0.61 to 1.02	0.07
30-d mortality	0.8%	0.6%	0.61	0.24 to 1.57	0.31
Survival at 5 y	64%	64%	1.06	0.89 to 1.28	0.47

CI: confidence interval; IMRT: intensity-modulated radiotherapy; OR: odds ratio; 3D-CRT: three-dimensional conformal radiation.

## EVIDENCE SUMMARY

For individuals who have cancer of the abdomen or pelvis who receive IMRT, the evidence includes small randomized controlled trials (RCTs), nonrandomized comparative studies, and case series. Relevant outcomes are OS, change in disease status, quality of life, and treatment-related morbidity.

For individuals who have gastrointestinal tract cancer who receive IMRT, the evidence includes nonrandomized comparative studies and retrospective series. IMRT has been compared with three-dimensional conformal radiation (3D-CRT) for the treatment of anal, stomach, hepatobiliary, and pancreatic cancers, with some studies reporting longer OS and decreased toxicity with IMRT. The evidence on hepatobiliary cancer includes a series with historical controls that found an increase in median survival with no difference in toxicity. Two comparative studies (one prospective, one retrospective) were identified on IMRT for pancreatic cancer. The prospective comparative study found an increase in survival with a reduction in gastrointestinal (GI) toxicity, while the retrospective study found a decrease in GI toxicity. The available comparative evidence, together with dosimetry studies of organs at risk, suggests

that IMRT may improve survival and decrease toxicity compared to 3D-CRT in patients with GI cancers. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have gynecologic cancer who receive IMRT, the evidence includes two randomized controlled trials (RCTs) and several nonrandomized comparative studies. There is limited comparative evidence on survival outcomes following IMRT or 3D-CRT. However, available results are generally consistent that IMRT leads to a reduction in GI and GU toxicity. Based on evidence with other cancers of the pelvis and abdomen that are in close proximity to organs at risk, it is expected that OS with IMRT would be at least as good as 3D-CRT, with a decrease in toxicity. A reduction in GI toxicity is likely to improve the quality of life in patients with gynecologic cancer. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have anal cancer who receive IMRT, the evidence includes a small RCT with 20 patients, nonrandomized comparative studies, and case series. Relevant outcomes are overall survival, disease-specific survival, quality of life, and treatment-related morbidity. Survival outcomes have not differed significantly between IMRT and CRT. Recent studies have found IMRT with chemotherapy for the treatment of anal cancer reduces acute and late adverse events better than 3D-CRT with chemotherapy. The comparative data on use of IMRT versus 3D-CRT in chemoradiotherapy for anal cancer has shown reductions primarily in GI toxicity. A reduction in GI toxicity is likely to improve the quality of life in patients with anorectal cancer. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have rectal cancer who receive IMRT, the evidence includes retrospective nonrandomized comparative studies. Results have been mixed, with lower GU and GI toxicity reported, but also higher rates of sphincter loss surgery and positive margins in those treated with IMRT. In addition, the evidence is limited study heterogeneity and the retrospective nature of the existing studies.

## PRACTICE GUIDELINE SUMMARY

### NATIONAL COMPREHENSIVE CANCER NETWORK

#### Anal Carcinoma

The National Comprehensive Cancer Network (NCCN) guidelines for anal carcinoma (v.3.2023) state in the Principles of Radiation Therapy that “The consensus of the panel is that intensity-modulated RT (IMRT) is preferred over 3D conformal RT in the treatment of anal carcinoma.”<sup>[134]</sup>

#### Biliary Tract Cancers

The NCCN guidelines for biliary tract cancers (v.2.2023) state<sup>[135]</sup>:

- For adjuvant RT, “Postoperative RT using conventional 3D conformal RT or IMRT is an option for resected extrahepatic cholangiocarcinoma and gallbladder cancer.”
- For unresectable tumors, “All tumors irrespective of location may be amenable to RT (3D-CRT, IMRT, or SBRT)”

#### Cervical Cancer

The NCCN guidelines for cervical cancer (v.1.2024) state that “IMRT is preferred to minimize toxicities in definitive treatment of the pelvis with or without para-aortic treatment. Additionally, IMRT is helpful in minimizing the dose to the bowel and other critical structures in the post-hysterectomy setting and in treating the para-aortic nodes when necessary...However, conformal external beam therapies such as IMRT...should not be used ...in the treatment of central disease in patients with an intact cervix”<sup>[136]</sup>

### **Colon Cancer**

The NCCN guidelines for colon cancer (v.3.2023) state, “IMRT is preferred for unique clinical situations such as reirradiation of previously treated patients with recurrent disease or unique anatomical situations where IMRT facilitates the delivery of recommended target volume doses while respecting accepted normal tissue dose-volume constraints.”<sup>[137]</sup>

### **Esophageal and Esophagogastric Junction Cancer**

The NCCN guidelines for esophageal and esophagogastric junction cancers (v.3.2023) state that IMRT “is appropriate in clinical settings where reduction in dose to organs at risk (e.g., heart, lungs) is required that cannot be achieved by 3-D techniques.”<sup>[138]</sup>

### **Gastric Cancer**

The NCCN guideline (v.2.2023) for gastric cancer indicates that “CT simulation and conformity treatment planning should be used with either 3D-CRT or IMRT.”<sup>[139]</sup> In addition, target volumes need to be carefully defined and encompassed while taking into account variations in stomach filling and respiratory motion.

### **Hepatocellular Carcinoma**

The NCCN guideline for hepatocellular carcinoma (v.2.2023) states, “All tumors irrespective of the location may be amenable to RT (3D conformal RT, intensity-modulated RT [IMRT], or stereotactic body RT [SBRT]). Image-guided RT is strongly recommended when using RT, IMRT, and SBRT to improve treatment accuracy and reduce treatment related toxicity.”<sup>[140]</sup>

### **Lung Cancer**

NCCN guideline (v.3.2023) for non-small-cell lung cancer indicate that “More advanced technologies are appropriate when needed to deliver curative RT safely.” These technologies include (but are not limited to) IMRT/VMAT. “Nonrandomized comparisons of using advanced technologies demonstrate reduced toxicity and improved survival versus older techniques.”<sup>[141]</sup>

NCCN guideline (v.1.2024) for small cell lung cancer indicate “Use of more advanced technologies is appropriate when needed to deliver adequate tumor dose while respecting normal tissue dose constraints.” IMRT is included in the technologies listed and “is preferred over 3D conformal external-beam RT (CRT) on the basis of reduced toxicity in the setting of concurrent chemotherapy/RT.”<sup>[142]</sup>

### **Malignant Pleural Mesothelioma**

Guidelines from NCCN on treatment of malignant pleural mesothelioma (v.1.2023) state “Use of highly conformal radiation technology [IMRT] is the preferred choice based on comprehensive consideration of target coverage and clinically relevant normal tissue tolerance.”<sup>[143]</sup>

## Prostate Cancer

The NCCN guidelines (v.4.2023) for prostate cancer indicate, in the principles of radiotherapy (RT) for primary external beam radiation therapy, “highly conformal radiotherapy techniques should be used to treat localized prostate cancer”.<sup>[144]</sup> A reference in the discussion section indicates IMRT is preferred over 3D-CRT because it seems to decrease salvage therapy rates while the risk of adverse effects such as gastrointestinal toxicities are reduced with IMRT.

NCCN states that “evidence supports offering adjuvant/salvage RT in most men with adverse pathologic features or detectable PSA and no evidence of disseminated disease.” It goes on to provide the following recommendations:

- Indications for adjuvant RT include pT3 disease, positive margins, or seminal vesicle involvement.
- Indications for salvage RT include an undetectable PSA that becomes detectable and then increases on two subsequent measurements or a PSA that remains persistently detectable after radical prostatectomy.
- The preferred dose/fractionation is moderate hypofractionation, scheduled as 3 Gy x 20 fx, 2.7 Gy x 26 fx, or 2.5 Gy x 28 fx for very low to very high risk and regional N1 disease, and 2.75 Gy x 20 fx for low volume M1.
- The recommended prescribed doses for adjuvant/salvage post-prostatectomy RT are 64-72 Gy in standard fractionation.

## Pancreatic Cancer

NCCN guidelines (v.2.2023) for pancreatic adenocarcinoma state that “3-D conformal RT (3D-CRT), intensity-modulated RT (IMRT), and SBRT can result in improved planning target volume (PTV) coverage with decreased dose to OARs.”<sup>[145]</sup>

## Rectal Cancer

NCCN guidelines (v.5.2023) for rectal cancer state that “IMRT is preferred for reirradiation of previously treated patients with recurrent disease, patients treated postoperatively due to increased acute or later toxicity, or in unique anatomical situations.”<sup>[146]</sup>

## Small Bowel Adenocarcinoma

The NCCN guidelines (v.1.2023) state that for treatment to the duodenum, “When appropriate, advanced treatment planning, such as intensity-modulated RT (IMRT) should be considered to limit toxicity to adjacent normal organs.”<sup>[147]</sup>

## Soft Tissue Sarcoma

The NCCN guidelines for soft tissue sarcomas (v.2.2023) state for both retroperitoneal/intra-abdominal tumors and extremity/superficial trunk tumors, “When EBRT is used, sophisticated treatment planning with IMRT, IGRT and/or protons can be used to improve the therapeutic ratio”.<sup>[148]</sup>

## Thymus Tumors

The NCCN guidelines for thymomas and thymic carcinomas (v.1.2023) state that, “A minimum technological standard for RT is CT-planned 3-D conformal radiation therapy (3D-CRT).”<sup>[149]</sup>



The guidelines go on to state that, “More advanced technologies are appropriate when needed to deliver curative RT safely” including IMRT, which is preferred over 3D-CRT.

## **Uterine Cancer**

The NCCN guidelines for uterine neoplasms (v.1.2024) state, “Treating with IMRT technique is preferred to minimize toxicities in definitive treatment of the pelvis with or without para-aortic treatment.”<sup>[150]</sup>

## **Vulvar Cancer**

The NCCN guidelines for vulvar cancer (v.2.2024) state, “Advanced techniques such as IMRT, image-guided RT (IGRT), and interstitial high dose-rate (HDR) brachytherapy should be used to maximize dose to the target and minimize dose to normal tissues.”<sup>[151]</sup>

## **AMERICAN SOCIETY FOR RADIATION ONCOLOGY**

In 2020, American Society for Radiation Oncology (ASTRO) published an evidence-based clinical practice guideline on radiation therapy for the treatment of nonmetastatic cervical cancer. Regarding the use of IMRT, the guideline makes the following recommendations:

1. “In women with cervical cancer treated with postoperative RT with or without chemotherapy, IMRT is recommended to decrease acute and chronic toxicity.” Strength of recommendation: Strong. Quality of evidence: Moderate (acute) Low (chronic)
2. “In women with cervical cancer treated with definitive RT with or without chemotherapy, IMRT is conditionally recommended to decrease acute and chronic toxicity.” Strength of recommendation: Conditional. Quality of evidence: Moderate (acute) Moderate (chronic)

The 2019 ASTRO clinical practice guideline on radiation therapy for pancreatic cancer recommended that for patients receiving radiotherapy for localized pancreatic cancer, “modulated treatment techniques such as IMRT and VMAT for planning and delivery of both conventionally fractionated and hypofractionated RT are recommended. (Strength of recommendation: Strong; Quality of evidence: Moderate).”<sup>[152]</sup>

A 2021 ASTRO guideline on radiation therapy for soft tissue sarcoma recommended IMRT, including VMAT “for patients with primary, localized extremity and truncal STS, [...] to minimize dose to OARs and reduce toxicity. (Strength of Recommendation: Strong; Quality of Evidence: Moderate).”<sup>[153]</sup> The guideline included the following implementation remark: “3-D CRT may be preferred in certain clinical scenarios to better spare OARs or reduce integral dose.”

ASTRO also published a 2021 guideline on radiation therapy for rectal cancer. This guideline states that “For patients with rectal cancer treated with RT, an IMRT/VMAT technique is conditionally recommended.”<sup>[154]</sup> Implementation remark: IMRT/VMAT may be beneficial when the external iliac nodes and/or the inguinal nodes require treatment or when 3-D conformal techniques may confer a higher risk for toxicity.”

A 2022 collaborative ASTRO/American Urological Association (AUA) guidelines on clinically localized prostate cancer were published.<sup>[155]</sup> The Guideline includes in its Principles of Radiation:

- “Clinicians should utilize available target localization, normal tissue avoidance, simulation, advanced treatment planning/delivery, and image-guidance procedures to

optimize the therapeutic ratio of external beam radiation therapy delivered for prostate cancer.

- “When treating the pelvic lymph nodes with radiation, clinicians should utilize intensity-modulated radiation therapy (IMRT) with doses between 45 Gy to 52 Gy” (Strong Recommendation; Evidence Level: Grade B)

## THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

The American Society of Clinical Oncology (ASCO) published a guideline on the treatment of malignant pleural mesothelioma in 2018.<sup>[156]</sup> For palliative radiation therapy, the guideline includes a strong, evidence-based recommendation stating “electrons, 2D, 3D, and IMRT may be considered appropriate techniques depending on location of the treatment target and organs at risk.” For adjuvant or neoadjuvant hemithoracic radiation therapy, the guideline includes the strong, evidence-based recommendation, “3D or IMRT may be offered, respecting guidelines of organs at risk.”

## SUMMARY

The available research on intensity modulated radiotherapy (IMRT) suggests that for certain cancers of the thorax, abdomen, pelvis, and extremities, IMRT may lead to clinical outcomes comparable with 3D-conformal radiation therapy (CRT) and may reduce radiation exposure to surrounding critical structures such as the heart. Therefore, IMRT may be considered medically necessary for the treatment of cancers of the thorax, abdomen, pelvis, and extremities when policy criteria are met.

For all other indications within the thorax, abdomen, pelvis, and extremities, intensity-modulated radiotherapy (IMRT) has not been shown to improve net health outcomes compared to other treatment modalities. Therefore, except in the select group of patients identified in the policy criteria, IMRT is not medically necessary for the treatment of all other cancers of the thorax, abdomen, pelvis, and extremities.

Hypofractionation, the use of fewer treatment sessions with higher doses, is supported by the evidence and preferred by clinical practice guidelines for prostate cancer in the clinical contexts outlined in the policy criteria. When a longer conventional fractionation regimen is planned, a note may be provided explaining clinical rationale for that regimen rather than hypofractionation. Therefore, in the clinical contexts for which the policy criteria indicate that hypofractionation is preferred, if no clinical rationale for its use is provided, conventionally fractionated intensity modulated radiotherapy (IMRT) is considered not medically necessary.

## REFERENCES

1. Bezjak A, Rumble RB, Rodrigues G, et al. Intensity-modulated radiotherapy in the treatment of lung cancer. *Clin Oncol (R Coll Radiol)*. 2012;24(7):508-20. PMID: 22726417
2. Liao ZX, Komaki RR, Thames HD, Jr., et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. *Int J Radiat Oncol Biol Phys*. 2010;76(3):775-81. PMID: 19515503

3. Yom SS, Liao Z, Liu HH, et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. *Int J Radiat Oncol Biol Phys*. 2007;68:94-102. PMID: 17321067
4. Louie AV, Granton PV, Fairchild A, et al. Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE): A Phase 3 Randomized Clinical Trial. *JAMA Oncol*. 2022;8(4):1-7. PMID: 35201290
5. Peng J, Pond G, Donovan E, et al. A Comparison of Radiation Techniques in Patients Treated With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer. *Int J Radiat Oncol Biol Phys*. 2020;106(5):985-92. PMID: 32007366
6. Appel S, Bar J, Ben-Nun A, et al. Comparative effectiveness of intensity modulated radiation therapy to 3-dimensional conformal radiation in locally advanced lung cancer: pathological and clinical outcomes. *Br J Radiol*. 2019;92(1097):20180960. PMID: 30864828
7. Koshy M, Malik R, Spiotto M, et al. Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy. *Lung cancer (Amsterdam, Netherlands)*. 2017;108:222-27. PMID: 28625640
8. Chun SG, Hu C, Choy H, et al. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2017;35(1):56-62. PMID: 28034064
9. Ling DC, Hess CB, Chen AM, et al. Comparison of Toxicity Between Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy for Locally Advanced Non-small-cell Lung Cancer. *Clinical lung cancer*. 2016;17(1):18-23. PMID: 26303127
10. Harris JP, Murphy JD, Hanlon AL, et al. A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2014;88(4):872-84. PMID: 24495591
11. Shirvani SM, Juloori A, Allen PK, et al. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2013;87(1):139-47. PMID: 23920393
12. Lan K, Zhu J, Zhang J, et al. Propensity score-based comparison of survival and radiation pneumonitis after definitive chemoradiation for esophageal cancer: Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy. *Radiother Oncol*. 2020;149:228-35. PMID: 32474127
13. Ito M, Kodaira T, Tachibana H, et al. Clinical results of definitive chemoradiotherapy for cervical esophageal cancer: Comparison of failure pattern and toxicities between intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy. *Head & neck*. 2017;39(12):2406-15. PMID: 28960561
14. Haefner MF, Lang K, Verma V, et al. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity. *Radiat Oncol*. 2017;12(1):131. PMID: 28810885
15. Xu D, Li G, Li H, et al. Comparison of IMRT versus 3D-CRT in the treatment of esophagus cancer: A systematic review and meta-analysis. *Medicine*. 2017;96(31):e7685. PMID: 28767597
16. Yang H, Feng C, Cai BN, et al. Comparison of three-dimensional conformal radiation therapy, intensity-modulated radiation therapy, and volumetric-modulated arc therapy in

- the treatment of cervical esophageal carcinoma. *Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus*. 2017;30(2):1-8. PMID: 27629865
17. Fu WH, Wang LH, Zhou ZM, et al. Comparison of conformal and intensity-modulated techniques for simultaneous integrated boost radiotherapy of upper esophageal carcinoma. *World journal of gastroenterology : WJG*. 2004;10(8):1098-102. PMID: 15069706
  18. Chandra A, Guerrero TM, Liu HH, et al. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. *Radiother Oncol*. 2005;77:247-53. PMID: 16298001
  19. Li JC, Liu D, Chen MQ, et al. Different radiation treatment in esophageal carcinoma: a clinical comparative study. *Journal of BUON : official journal of the Balkan Union of Oncology*. 2012;17(3):512-6. PMID: 23033291
  20. Lin SH, Merrell KW, Shen J, et al. Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. *Radiother Oncol*. 2017;123(3):376-81. PMID: 28455153
  21. Li CC, Chen CY, Chien CR. Comparison of intensity-modulated radiotherapy vs 3-dimensional conformal radiotherapy for patients with non-metastatic esophageal squamous cell carcinoma receiving definitive concurrent chemoradiotherapy: A population-based propensity-score-matched analysis. *Medicine*. 2018;97(22):e10928. PMID: 29851829
  22. Chi A, Liao Z, Nguyen NP, et al. Intensity-modulated radiotherapy after extrapleural pneumonectomy in the combined-modality treatment of malignant pleural mesothelioma. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2011;6(6):1132-41. PMID: 21532502
  23. Price A. What is the role of radiotherapy in malignant pleural mesothelioma? *The oncologist*. 2011;16(3):359-65. PMID: 21346022
  24. Chapman E, Berenstein EG, Dieguez M, et al. Radiotherapy for malignant pleural mesothelioma. *Cochrane Database Syst Rev*. 2006(3):CD003880. PMID: 16856023
  25. Foroudi F, Smith JG, Putt F, et al. High-dose palliative radiotherapy for malignant pleural mesothelioma. *Journal of medical imaging and radiation oncology*. 2017. PMID: 28727277
  26. Shaikh F, Zauderer MG, von Reibnitz D, et al. Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2017;12(6):993-1000. PMID: 28341225
  27. Giannopoulou A, Gkiozos I, Harrington KJ, et al. Thymoma and radiation therapy: a systematic review of medical treatment. *Expert review of anticancer therapy*. 2013;13(6):759-66. PMID: 23773107
  28. Wang J, Song Y, Liu X, et al. Comparison of outcome and toxicity of postoperative intensity-modulated radiation therapy with two-dimensional radiotherapy in patients with soft tissue sarcoma of extremities and trunk. *Cancer Medicine*. 2019;8(3):902-09. PMID: 30811111
  29. Folkert MR, Singer S, Brennan MF, et al. Comparison of Local Recurrence With Conventional and Intensity-Modulated Radiation Therapy for Primary Soft-Tissue Sarcomas of the Extremity. *Journal of Clinical Oncology*. 2014;32(29):3236-41. PMID: 25185087
  30. Alektiar KM, Brennan MF, Healey JH, et al. Impact of Intensity-Modulated Radiation Therapy on Local Control in Primary Soft-Tissue Sarcoma of the Extremity. *Journal of Clinical Oncology*. 2008;26(20):3440-44. PMID: 18612160

31. El-Bared N, Taussky D, Mehiri S, et al. Preoperative Intensity Modulated Radiation Therapy for Retroperitoneal Sarcoma. *Technology in Cancer Research & Treatment*. 2014;13(3):211-16. PMID: 23919397
32. Roeder F, Ulrich A, Habl G, et al. Clinical Phase I/II trial to Investigate Preoperative Dose-Escalated Intensity-Modulated Radiation Therapy (IMRT) and Intraoperative Radiation Therapy (IORT) in patients with retroperitoneal soft tissue sarcoma: interim analysis. *BMC Cancer*. 2014;14(1):617. PMID:
33. Wang J, Wang S, Song Y, et al. Postoperative intensity-modulated radiation therapy provides favorable local control and low toxicities in patients with soft tissue sarcomas in the extremities and trunk wall. *Onco Targets Ther*. 2015;8:2843-7. PMID: 26491357
34. Coper PF, Olsen J, DeWees T, et al. Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience. *Radiat Oncol*. 2017;12(1):198. PMID: 29216884
35. Folkert MR, Casey DL, Berry SL, et al. Femoral Fracture in Primary Soft-Tissue Sarcoma of the Thigh and Groin Treated with Intensity-Modulated Radiation Therapy: Observed versus Expected Risk. *Annals of surgical oncology*. 2019;26(5):1326-31. PMID: 30706225
36. O'Sullivan B, Griffin AM, Dickie CI, et al. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. *Cancer*. 2013;119(10):1878-84. PMID: 23423841
37. Ren F, Li S, Zhang Y, et al. Efficacy and safety of intensity-modulated radiation therapy versus three-dimensional conformal radiation treatment for patients with gastric cancer: a systematic review and meta-analysis. *Radiat Oncol*. 2019;14(1):84. PMID: 31118042
38. Milano MT, Garofalo MC, Chmura SJ, et al. Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. *Br J Radiol*. 2006;79(942):497-503. PMID: 16714752
39. Boda-Heggemann J, Hofheinz RD, Weiss C, et al. Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer. *Int J Radiat Oncol Biol Phys*. 2009;75(4):1187-95. PMID: 19409725
40. Boda-Heggemann J, Weiss C, Schneider V, et al. Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer. *Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]*. 2013;189(5):417-23. PMID: 23558673
41. Minn AY, Hsu A, La T, et al. Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. *Cancer*. 2010;116(16):3943-52. PMID: 20564136
42. Li P, Sheng LM, Deng QH, et al. Treatment of high-risk gastric cancer postoperatively using intensity-modulated radiotherapy: a single-institution experience. *Hepato-gastroenterology*. 2012;59(113):159-63. PMID: 22260830
43. Chakravarty T, Crane CH, Ajani JA, et al. Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma. *Int J Radiat Oncol Biol Phys*. 2012;83(2):581-6. PMID: 22137021
44. Yu C, Yu R, Zhu W, et al. Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery. *Journal of cancer research and clinical oncology*. 2012;138(2):255-9. PMID: 22105898
45. Bahl A, Kapoor R, Tomar P, et al. Dosimetric comparison of doses to organs at risk using 3-D conformal radiotherapy versus intensity modulated radiotherapy in

- postoperative radiotherapy of periampullary cancers: implications for radiation dose escalation. *JOP : Journal of the pancreas*. 2013;14(1):39-43. PMID: 23306333
46. Qiu M, Peng XC, Bi F, et al. Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer. *Med Oncol*. 2015;32(7):191. PMID: 26025485
  47. Zhang T, Liang ZW, Han J, et al. Double-arc volumetric modulated therapy improves dose distribution compared to static gantry IMRT and 3D conformal radiotherapy for adjuvant therapy of gastric cancer. *Radiat Oncol*. 2015;10:114. PMID: 25986069
  48. Wang X, Shen Y, Zhu H, et al. A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection. *Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association*. 2015. PMID: 25609451
  49. Haneder S, Budjan JM, Schoenberg SO, et al. Dose-dependent changes in renal (1)H-/(23)Na MRI after adjuvant radiochemotherapy for gastric cancer. *Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]*. 2015;191(4):356-64. PMID: 25445156
  50. Matoba M, Tsuchiya H, Kondo T, et al. Stereotactic body radiotherapy delivered with IMRT for oligometastatic regional lymph node metastases in hepatocellular carcinoma: a single-institutional study. *Journal of radiation research*. 2020;61(5):776-83. PMID: 32845298
  51. Fuller CD, Dang ND, Wang SJ, et al. Image-guided intensity-modulated radiotherapy (IG-IMRT) for biliary adenocarcinomas: Initial clinical results. *Radiother Oncol*. 2009;92(2):249-54. PMID: 19324442
  52. Jang JW, Kay CS, You CR, et al. Simultaneous multitarget irradiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases. *Int J Radiat Oncol Biol Phys*. 2009;74(2):412-8. PMID: 18963538
  53. McIntosh A, Hagspiel KD, Al-Osaimi AM, et al. Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. *Cancer*. 2009;115(21):5117-25. PMID: 19642177
  54. Ren ZG, Zhao JD, Gu K, et al. Three-dimensional conformal radiation therapy and intensity-modulated radiation therapy combined with transcatheter arterial chemoembolization for locally advanced hepatocellular carcinoma: an irradiation dose escalation study. *Int J Radiat Oncol Biol Phys*. 2011;79(2):496-502. PMID: 20421145
  55. Kang MK, Kim MS, Kim SK, et al. High-dose radiotherapy with intensity-modulated radiation therapy for advanced hepatocellular carcinoma. *Tumori*. 2011;97(6):724-31. PMID: 22322838
  56. Lee KJ, Yoon HI, Chung MJ, et al. A Comparison of Gastrointestinal Toxicities between Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy for Pancreatic Cancer. *Gut and liver*. 2016;10(2):303-9. PMID: 26470767
  57. Prasad S, Cambridge L, Huguet F, et al. Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer. *Practical radiation oncology*. 2016;6(2):78-85. PMID: 26577010
  58. Fuss M, Wong A, Fuller CD, et al. Image-guided intensity-modulated radiotherapy for pancreatic carcinoma. *Gastrointest Cancer Res*. 2007;1(1):2-11. PMID: 19262697
  59. Milano MT, Chmura SJ, Garofalo MC, et al. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. *Int J Radiat Oncol Biol Phys*. 2004;59(2):445-53. PMID: 15145161

60. Ben-Josef E, Shields AF, Vaishampayan U, et al. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. *Int J Radiat Oncol Biol Phys.* 2004;59(2):454-9. PMID: 15145162
61. Yovino S, Poppe M, Jabbour S, et al. Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. *Int J Radiat Oncol Biol Phys.* 2011;79(1):158-62. PMID: 20399035
62. Ling TC, Slater JM, Mifflin R, et al. Evaluation of normal tissue exposure in patients receiving radiotherapy for pancreatic cancer based on RTOG 0848. *J Gastrointest Oncol.* 2015;6:108-14. PMID: 25830030
63. Wang Z, Ren ZG, Ma NY, et al. Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: a mono-institutional retrospective analysis. *Radiat Oncol.* 2015;10:14. PMID: 25575617
64. Lin AJ, Kidd E, Dehdashti F, et al. Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer. *Int J Radiat Oncol Biol Phys.* 2019;103(5):1088-97. PMID: 30445171
65. Chopra S, Gupta S, Kannan S, et al. Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 2021;39(33):3682-92. PMID: 34506246
66. Wortman BG, Post CCB, Powell ME, et al. Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. *Int J Radiat Oncol Biol Phys.* 2022;112(2):390-99. PMID: 34610387
67. Klopp AH, Yeung AR, Deshmukh S, et al. Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 2018;36(24):2538-44. PMID: 29989857
68. Naik A, Gurjar OP, Gupta KL, et al. Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study. *Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.* 2016;20(5):370-6. PMID: 27368915
69. Gandhi AK, Sharma DN, Rath GK, et al. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study. *Int J Radiat Oncol Biol Phys.* 2013;87(3):542-8. PMID: 24074927
70. Yu C, Zhu W, Ji Y, et al. A comparative study of intensity-modulated radiotherapy and standard radiation field with concurrent chemotherapy for local advanced cervical cancer. *European journal of gynaecological oncology.* 2015;36(3):278-82. PMID: 26189253
71. Zhang K, Wang H, Wang Z, et al. Intensity-modulated radiation therapy (IMRT)-based concurrent chemoradiotherapy (CCRT) with Endostar in patients with pelvic locoregional recurrence of cervical cancer: Results from a hospital in the Qinghai-Tibet Plateau. *Medicine.* 2020;99(49):e21966. PMID: 33285664
72. Contreras J, Srivastava A, Chundury A, et al. Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.* 2020;30(8):1157-61. PMID: 32527770

73. Yamamoto T, Umezawa R, Tokunaga H, et al. Clinical experience of pelvic radiotherapy or chemoradiotherapy for postoperative uterine cervical cancer using intensity-modulated radiation therapy. *Journal of radiation research*. 2020;61(3):470-78. PMID: 32100833
74. Vavassori A, Riva G, Spoto R, et al. High precision radiotherapy including intensity-modulated radiation therapy and pulsed-dose-rate brachytherapy for cervical cancer: a retrospective monoinstitutional study. *J Contemp Brachytherapy*. 2019;11(6):516-26. PMID: 31969909
75. Mell LK, Xu R, Yashar CM, et al. Phase 1 Trial of Concurrent Gemcitabine and Cisplatin with Image Guided Intensity Modulated Radiation Therapy for Locoregionally Advanced Cervical Carcinoma. *Int J Radiat Oncol Biol Phys*. 2020;107(5):964-73. PMID: 32334034
76. Chen JL, Huang YS, Huang CY, et al. Impact of adjuvant radiotherapy on the survival of women with optimally resected stage III endometrial cancer in the era of modern radiotherapy: a retrospective study. *Radiat Oncol*. 2020;15(1):72. PMID: 32252781
77. Kumar T, Schernberg A, Busato F, et al. Correlation between pelvic bone marrow radiation dose and acute hematological toxicity in cervical cancer patients treated with concurrent chemoradiation. *Cancer Manag Res*. 2019;11:6285-97. PMID: 31372035
78. Lei C, Ma S, Huang M, et al. Long-Term Survival and Late Toxicity Associated With Pelvic Intensity Modulated Radiation Therapy (IMRT) for Cervical Cancer Involving CT-Based Positive Lymph Nodes. *Frontiers in oncology*. 2019;9:520. PMID: 31275853
79. Shih KK, Hajj C, Kollmeier M, et al. Impact of postoperative intensity-modulated radiation therapy (IMRT) on the rate of bowel obstruction in gynecologic malignancy. *Gynecologic oncology*. 2016;143(1):18-21. PMID: 27486131
80. Mundt AJ, Roeske JC, Lujan AE, et al. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. *Gynecologic oncology*. 2001;82(3):456-63. PMID: 11520140
81. Mundt AJ, Lujan AE, Rotmensch J, et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. *Int J Radiat Oncol Biol Phys*. 2002;52(5):1330-7. PMID: 11955746
82. Brixey CJ, Roeske JC, Lujan AE, et al. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. *Int J Radiat Oncol Biol Phys*. 2002;54(5):1388-96. PMID: 12459361
83. Mundt AJ, Mell LK, Roeske JC. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. *Int J Radiat Oncol Biol Phys*. 2003;56(5):1354-60. PMID: 12873680
84. Roeske JC, Bonta D, Mell LK, et al. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. *Radiother Oncol*. 2003;69(2):201-7. PMID: 14643959
85. Lv Y, Wang F, Yang L, et al. Intensity-modulated whole pelvic radiotherapy provides effective dosimetric outcomes for cervical cancer treatment with lower toxicities. *Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique*. 2014;18(8):745-52. PMID: 25451672
86. Xu KM, Rajagopalan MS, Kim H, et al. Extended field intensity modulated radiation therapy for gynecologic cancers: Is the risk of duodenal toxicity high? *Practical radiation oncology*. 2015;5(4):e291-7. PMID: 25532491
87. Chen MF, Tseng CJ, Tseng CC, et al. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic



- radiotherapy: comparison with conventional radiotherapy. *Int J Radiat Oncol Biol Phys*. 2007;67(5):1438-44. PMID: 17394944
88. Chen MF, Tseng CJ, Tseng CC, et al. Adjuvant concurrent chemoradiotherapy with intensity-modulated pelvic radiotherapy after surgery for high-risk, early stage cervical cancer patients. *Cancer J*. 2008;14(3):200-6. PMID: 18536561
  89. Chen CC, Wang L, Lu CH, et al. Comparison of clinical outcomes and toxicity in endometrial cancer patients treated with adjuvant intensity-modulated radiation therapy or conventional radiotherapy. *Journal of the Formosan Medical Association = Taiwan yi zhi*. 2014;113(12):949-55. PMID: 24144528
  90. Shih KK, Milgrom SA, Abu-Rustum NR, et al. Postoperative pelvic intensity-modulated radiotherapy in high risk endometrial cancer. *Gynecologic oncology*. 2013;128(3):535-9. PMID: 23174538
  91. Beriwal S, Shukla G, Shinde A, et al. Preoperative intensity modulated radiation therapy and chemotherapy for locally advanced vulvar carcinoma: analysis of pattern of relapse. *Int J Radiat Oncol Biol Phys*. 2013;85(5):1269-74. PMID: 23273997
  92. Hsieh CH, Wei MC, Lee HY, et al. Whole pelvic helical tomotherapy for locally advanced cervical cancer: technical implementation of IMRT with helical tomotherapy. *Radiat Oncol*. 2009;4:62. PMID: 20003321
  93. Hasselle MD, Rose BS, Kochanski JD, et al. Clinical Outcomes of Intensity-Modulated Pelvic Radiation Therapy for Carcinoma of the Cervix. *Int J Radiat Oncol Biol Phys*. 2010. PMID: 20708346
  94. Frank SJ, Rosenthal DI, Petsuksiri J, et al. Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure. *Int J Radiat Oncol Biol Phys*. 2010;78(4):1005-10. PMID: 20207504
  95. Rochet N, Sterzing F, Jensen AD, et al. Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study. *Int J Radiat Oncol Biol Phys*. 2010;76(5):1382-9. PMID: 19628341
  96. Macchia G, Cilla S, Ferrandina G, et al. Postoperative intensity-modulated radiotherapy in low-risk endometrial cancers: final results of a Phase I study. *Int J Radiat Oncol Biol Phys*. 2010;76(5):1390-5. PMID: 19800180
  97. Marnitz S, Kohler C, Burova E, et al. Helical tomotherapy with simultaneous integrated boost after laparoscopic staging in patients with cervical cancer: analysis of feasibility and early toxicity. *Int J Radiat Oncol Biol Phys*. 2012;82(2):e137-43. PMID: 21600704
  98. Chen C, Shen HL, Yang J, et al. Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib. *Journal of cancer research and clinical oncology*. 2011;137(1):9-17. PMID: 20229271
  99. Schwarz JK, Wahab S, Grigsby PW. Prospective phase I-II trial of helical tomotherapy with or without chemotherapy for postoperative cervical cancer patients. *Int J Radiat Oncol Biol Phys*. 2011;81(5):1258-63. PMID: 20932657
  100. Du XL, Jiang T, Sheng XG, et al. PET/CT scanning guided intensity-modulated radiotherapy in treatment of recurrent ovarian cancer. *European journal of radiology*. 2012;81(11):3551-6. PMID: 22521528
  101. Zhang G, Fu C, Zhang Y, et al. Extended-field intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy for postoperative cervical cancer with common iliac or para-aortic lymph node metastases: a retrospective review in a single institution. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2012;22(7):1220-5. PMID: 22854654

102. Jensen LG, Hasselle MD, Rose BS, et al. Outcomes for patients with cervical cancer treated with extended-field intensity-modulated radiation therapy and concurrent cisplatin. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2013;23(1):119-25. PMID: 23262521
103. Jhingran A, Winter K, Portelance L, et al. A phase II study of intensity modulated radiation therapy to the pelvis for postoperative patients with endometrial carcinoma: radiation therapy oncology group trial 0418. *Int J Radiat Oncol Biol Phys*. 2012;84(1):e23-8. PMID: 22543211
104. Chen CC, Wang L, Lu CH, et al. Comparison of clinical outcomes and toxicity in endometrial cancer patients treated with adjuvant intensity-modulated radiation therapy or conventional radiotherapy. *Journal of the Formosan Medical Association = Taiwan yi zhi*. 2013. PMID: 24144528
105. Kidd EA, Siegel BA, Dehdashti F, et al. Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer. *Int J Radiat Oncol Biol Phys*. 2010;77(4):1085-91. PMID: 19880262
106. Du XL, Tao J, Sheng XG, et al. Intensity-modulated radiation therapy for advanced cervical cancer: a comparison of dosimetric and clinical outcomes with conventional radiotherapy. *Gynecologic oncology*. 2012;125(1):151-7. PMID: 22198339
107. Klopp AH, Moughan J, Portelance L, et al. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer. *Int J Radiat Oncol Biol Phys*. 2013;86(1):83-90. PMID: 23582248
108. Erpolat OP, Alco G, Caglar HB, et al. Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study. *European journal of gynaecological oncology*. 2014;35(1):62-6. PMID: 24654465
109. Yu T, Zhang Q, Zheng T, et al. The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures. *PloS one*. 2016;11(5):e0154499. PMID: 27171271
110. Bauman G, Rumble RB, Chen J, et al. Intensity-modulated radiotherapy in the treatment of prostate cancer. *Clin Oncol (R Coll Radiol)*. 2012;24(7):461-73. PMID: 22673744
111. Yong JH, Beca J, McGowan T, et al. Cost-effectiveness of intensity-modulated radiotherapy in prostate cancer. *Clin Oncol (R Coll Radiol)*. 2012;24(7):521-31. PMID: 22705100
112. Wilt TJ ST, Taylor B et al. Comparative effectiveness of therapies for clinically localized prostate cancer. Comparative Effectiveness Review No. 13. [cited 8/5/2022]. 'Available from:' <https://effectivehealthcare.ahrq.gov/products/prostate-cancer/research>.
113. Ip S DT, Yu W, et al. Radiation Therapy for Localized Prostate Cancer: an Update. Technology Assessment Report. [cited 8/5/2022]. 'Available from:' <https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id69ta.pdf>.
114. Sun F, Oyesanmi O, Fontanarosa J, et al. Therapies for Clinically Localized Prostate Cancer: Update of a 2008 Systematic Review. Agency for Healthcare Research and Quality (Comparative Effectiveness Reviews, No. 146). [cited 8/5/2022]. 'Available from:' <https://www.ncbi.nlm.nih.gov/books/NBK269320/>.
115. Hummel S SE, Hemingway P, Stevenson MD, Rees A. Intensity modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. *Health Technology Assessment*. 2011;14:1-137. PMID:

116. Leite ETT, Ramos CCA, Ribeiro VAB, et al. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial. *Int J Radiat Oncol Biol Phys.* 2021;109(5):1263-70. PMID: 33346091
117. Katayama S, Habl G, Kessel K, et al. Helical intensity-modulated radiotherapy of the pelvic lymph nodes with integrated boost to the prostate bed - initial results of the PLATIN 3 Trial. *BMC Cancer.* 2014;14:20. PMID: 24422782
118. Katayama S, Striecker T, Kessel K, et al. Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial. *Int J Radiat Oncol Biol Phys.* 2014;90(4):926-33. PMID: 25216858
119. Corbin KS, Kunnavakkam R, Eggener SE, et al. Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality of life. *Practical radiation oncology.* 2013;3(2):138-44. PMID: 24674317
120. Massaccesi M, Cilla S, Deodato F, et al. Hypofractionated intensity-modulated radiotherapy with simultaneous integrated boost after radical prostatectomy: preliminary results of a phase II trial. *Anticancer Res.* 2013;33:2785-9. PMID: 23749942
121. Thompson IM, Valicenti RK, Albertsen P, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. *The Journal of urology.* 2013;190(2):441-9. PMID: 23707439
122. Alongi F, Fiorino C, Cozzarini C, et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. *Radiother Oncol.* 2009;93(2):207-12. PMID: 19766338
123. Hickey BE, James ML, Daly T, et al. Hypofractionation for clinically localized prostate cancer. *The Cochrane database of systematic reviews.* 2019;9(9):CD011462-CD62. PMID: 31476800
124. Rattan R, Kapoor R, Bahl A, et al. Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in carcinoma of anal canal: a prospective study. *Annals of translational medicine.* 2016;4(4):70. PMID: 27004217
125. Gul SK, Tepetam H, Yildiz F, et al. Revisiting the Radical Radiotherapy-Radiochemotherapy Results in Anal Canal Cancers: (TROD Gastrointestinal Group Study 02-005). *Clin Colorectal Cancer.* 2023;22(3):318-26. PMID: 37336706
126. Vendrely V, Lemanski C, Pommier P, et al. Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE. *Radiother Oncol.* 2023;183:109542. PMID: 36813175
127. Sauter M, Lombriser N, Bütikofer S, et al. Improved treatment outcome and lower skin toxicity with intensity-modulated radiotherapy vs. 3D conventional radiotherapy in anal cancer. *Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft [et al].* 2020;196(4):356-67. PMID: 31980834
128. Chuong MD, Freilich JM, Hoffe SE, et al. Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. *Gastrointest Cancer Res.* 2013;6(2):39-45. PMID: 23745158
129. Dewas CV, Maingon P, Dalban C, et al. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer? *Radiat Oncol.* 2012;7:201. PMID: 23190693

130. Dasgupta T, Rothenstein D, Chou JF, et al. Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. *Radiother Oncol.* 2013;107(2):189-94. PMID: 23692961
131. Milano MT, Jani AB, Farrey KJ, et al. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. *Int J Radiat Oncol Biol Phys.* 2005;63(2):354-61. PMID: 16168830
132. Wee CW, Kang HC, Wu HG, et al. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in rectal cancer treated with neoadjuvant concurrent chemoradiation: a meta-analysis and pooled-analysis of acute toxicity. *Jpn J Clin Oncol.* 2018;48(5):458-66. PMID: 29554287
133. Sun Z, Adam MA, Kim J, et al. Intensity-Modulated Radiation Therapy Is Not Associated with Perioperative or Survival Benefit over 3D-Conformal Radiotherapy for Rectal Cancer. *Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract.* 2017;21(1):106-11. PMID: 27510332
134. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Anal Carcinoma. v.3.2023. [cited 10/12/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/anal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf).
135. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Biliary Tract Cancers. v.2.2023. [cited 10/12/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/btc.pdf](https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf).
136. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Cervical Cancer. v.1.2024. [cited 10/12/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/cervical.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf).
137. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Colon Cancer. v.3.2023. [cited. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/colon.pdf](https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf).
138. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Esophageal and Esophagogastric Junction Cancers. v.3.2023. [cited 10/12/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/esophageal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf).
139. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Gastric Cancer v.2.2023. [cited 10/12/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/gastric.pdf](https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf).
140. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Hepatocellular Carcinoma. v.2.2023. [cited 10/12/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/hcc.pdf](https://www.nccn.org/professionals/physician_gls/pdf/hcc.pdf).
141. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Non-Small Cell Lung Cancer. v.3.2023. [cited 10/12/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf).
142. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Small Cell Lung Cancer. v.1.2024. [cited 10/12/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/sclc.pdf](https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf).
143. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Mesothelioma: Pleural v.1.2023. [cited 10/12/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/meso\\_pleural.pdf](https://www.nccn.org/professionals/physician_gls/pdf/meso_pleural.pdf).
144. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Prostate Cancer. v.4.2023. [cited 10/12/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/prostate.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf).

145. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Pancreatic Adenocarcinoma. v.2.2023. [cited 10/10/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/pancreatic.pdf](https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf).
146. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Rectal Cancer v.5.2023. [cited 10/12/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/rectal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf).
147. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Small Bowel Adenocarcinoma. v.1.2023. [cited 10/12/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/small\\_bowel.pdf](https://www.nccn.org/professionals/physician_gls/pdf/small_bowel.pdf).
148. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Soft Tissue Sarcoma. v.2.2023. [cited 10/12/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/sarcoma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf).
149. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Thymomas and Thymic Carcinomas. v.1.2023. [cited 10/12/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/thymic.pdf](https://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf).
150. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Uterine Neoplasms v.1.2024. [cited 10/12/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/uterine.pdf](https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf).
151. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Vulvar Cancer. v.2.2024. [cited 11/06/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/vulvar.pdf](https://www.nccn.org/professionals/physician_gls/pdf/vulvar.pdf).
152. Palta M, Godfrey D, Goodman KA, et al. Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. *Practical radiation oncology*. 2019;9(5):322-32. PMID: 31474330
153. Salerno KE, Alektiar KM, Baldini EH, et al. Radiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: Executive Summary of an ASTRO Clinical Practice Guideline. *Practical radiation oncology*. 2021;11(5):339-51. PMID: 34326023
154. Wo JY, Anker CJ, Ashman JB, et al. Radiation Therapy for Rectal Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. *Practical radiation oncology*. 2021;11(1):13-25. PMID: 33097436
155. Eastham JA. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline (2022). [cited 10/12/2023]. 'Available from:' <https://www.auanet.org/guidelines-and-quality/guidelines/clinically-localized-prostate-cancer-uaa/astro-guideline-2022>.
156. Kindler HL, Ismaila N, III SGA, et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. *Journal of Clinical Oncology*. 2018;36(13):1343-73. PMID: 29346042

## CODES

**NOTE:** The correct code to use for image fusion performed to provide enhanced delineation of target and normal critical structures is CPT code 77399 (Unlisted procedure, medical radiation physics, dosimetry and treatment devices, and special services); however, it is considered part of the treatment planning.

Codes	Number	Description
CPT	77301	Intensity modulated radiotherapy plan, including dose volume histograms for target and critical structure partial tolerance specification
	77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan

<b>Codes</b>	<b>Number</b>	<b>Description</b>
	77385	Intensity modulated radiation treatment deliver (IMRT), includes guidance and tracking, when performed; simple
	77386	;complex
HCPCS	G6015	Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session
	G6016	Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session

**Date of Origin:** July 2019